

Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer's disease

Leticia Peris,^{1,†,‡} Julie Parato,^{2,3,†} Xiaoyi Qu,^{2,†,§} Jean-Marc Soleilhac,¹ Fabien Lanté,¹ Atul Kumar,² Maria Elena Pero,^{2,4} José Martínez-Hernández,^{1,#} Charlotte Corrao,¹ Giulia Falivelli,¹ Floriane Payet,¹ Sylvie Gory-Fauré,¹ Christophe Bosc,¹ Marian Blanca Ramírez,² Andrew Sproul,² Jacques Brocard,¹ Benjamin Di Cara,⁵ Philippe Delagrangé,⁵ Alain Buisson,¹ Yves Goldberg,¹ Marie-Jo Moutin,^{1,‡} Francesca Bartolini^{2,‡} and Annie Andrieux^{1,‡}

1 Univ. Grenoble Alpes, Inserm, U1216, CEA, CNRS, Grenoble Institut Neurosciences, 38000 Grenoble, France

2 Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA

3 Department of Natural Sciences, SUNY ESC, 177 Livingston St 6th Floor, Brooklyn, NY 11201, USA

4 Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137, Naples, Italy

5 Institut de Recherche Servier, Croissy, France

[§]Present address: Genentech, San Francisco, CA 94080, USA

[#]Present address: Synaptic Structure Laboratory, Dept. Ciencias Médicas, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Facultad de Medicina, Universidad Castilla-La Mancha, 02008 Albacete, Spain

Correspondence to: Leticia Peris

Grenoble Institut Neurosciences, Site santé La Tronche, BP170, 38042 Grenoble, France

E-mail: leticia.peris@univ-grenoble-alpes.fr

Correspondence may also be addressed to: Francesca Bartolini

Department of Pathology & Cell Biology, Columbia University Irving Medical Center, 630 W. 168(th) Street, New York, NY 10032, USA

E-mail: fb2131@cumc.columbia.edu

Running title: Tubulin tyrosination in Alzheimer's disease

^{†,‡}**These authors contributed equally to this work.**

1 Abstract

2 Microtubules play fundamental roles in the maintenance of neuronal processes and in synaptic function
3 and plasticity. While dynamic microtubules are mainly composed of tyrosinated tubulin, long-lived
4 microtubules contain detyrosinated tubulin, suggesting that the tubulin tyrosination/detyrosination
5 cycle is a key player in the maintenance of microtubule dynamics and neuronal homeostasis, conditions
6 which go awry in neurodegenerative diseases. In the tyrosination/detyrosination cycle, the C-terminal
7 tyrosine of α -tubulin is removed by tubulin carboxypeptidases and re-added by tubulin tyrosine ligase.
8 Here we show that tubulin tyrosine ligase hemizygous mice exhibit decreased tyrosinated microtubules,
9 reduced dendritic spine density, and both synaptic plasticity and memory deficits. We further report
10 decreased tubulin tyrosine ligase expression in sporadic and familial Alzheimer's disease, and reduced
11 microtubule dynamics in human neurons harboring the familial APP-V717I mutation. Finally, we show
12 that synapses visited by dynamic microtubules are more resistant to oligomeric amyloid β peptide
13 toxicity and that expression of tubulin tyrosine ligase, by restoring microtubule entry into spines,
14 suppresses the loss of synapses induced by amyloid β peptide. Together, our results demonstrate that a
15 balanced tyrosination/detyrosination tubulin cycle is necessary for the maintenance of synaptic
16 plasticity, is protective against amyloid β peptide-induced synaptic damage, and that this balance is lost
17 in Alzheimer's disease, providing evidence that defective tubulin retyrosination may contribute to circuit
18 dysfunction during neurodegeneration in Alzheimer's disease.

19 **Keywords:** tubulin; microtubule; neuron; Alzheimer's disease; dendritic spines

20 **Abbreviations:** APP = Amyloid Precursor Protein; oA β = oligomeric Amyloid β peptide (1-42); TTL =
21 Tubulin Tyrosine Ligase; LTP = Long Term Potentiation; LTD = Long Term Depression; VASH1 = Vasohibin
22 1; VASH2 = Vasohibin 2; SVBP = Small Vasohibin Binding Protein; TTL^{+/-} = Tubulin Tyrosine Ligase
23 heterozygous; WT = Wild-Type; fEPSPs = field Excitatory PostSynaptic Potentials; I/O = Input/Output
24 curves; TBS = Theta Burst Stimulation; iPSCs = induced Pluripotent Stem Cells

25

1 Introduction

2 The neuronal microtubule cytoskeleton plays a fundamental role in the development and long-
3 term maintenance of axons and dendrites. Research over the past two decades has revealed that
4 dynamic microtubules, in particular, critically contribute to synaptic structure and function
5 within both pre- and postsynaptic compartments.^{1, 2} Dynamic microtubules regulate synaptic
6 vesicle cycling by providing paths for bidirectional transport between presynaptic terminals, a
7 rate-limiting step in exocytosis at sites of release.³⁻⁶ In dendritic spines, while the core
8 cytoskeletal structure consists of actin filaments, dynamic microtubules originating in the
9 dendritic shaft sporadically enter the spine head and directly impinge on the regulation of spine
10 composition and morphology.^{7, 8} Microtubule entry into spines is dependent on synaptic activity,
11 Ca^{2+} influx, actin polymerization, and correlates with changes in synaptic strength.⁹ In cultured
12 rodent hippocampal neurons and organotypic slices, stimulation of postsynaptic N-methyl-D-
13 aspartate receptors by chemical long term potentiation (LTP) protocols or glutamate photo-
14 release leads to higher frequency and longer duration of spine invasions by microtubules,
15 concurrent with spine enlargement.¹⁰⁻¹² Conversely, chemical induction of long term depression
16 (LTD) decreases microtubule invasions, indicating that microtubules targeting into spines are
17 sensitive to plasticity signals.¹³⁻¹⁵ Spine invasions, as well as synaptic plasticity, specifically
18 involve dynamic microtubules, as both invasions and LTP are blocked when microtubule
19 dynamics are inhibited by low doses of nocodazole¹¹ or taxol.^{8, 16} Consistent with these results,
20 efficient contextual fear conditioning in mice appears to require transient accumulation of
21 dynamic microtubules at dentate gyrus synapses.¹⁷ Together, these findings indicate that changes
22 in synaptic microtubule dynamics may affect both pre- and postsynaptic functions.

23 Microtubule dynamics rely on the intrinsic capacity of microtubules to alternate phases of
24 polymerization and depolymerization. Various cellular factors have been shown to modulate
25 microtubule dynamics including the nature of tubulin isoforms, GTP hydrolysis, microtubule
26 associated proteins and various post-translational modifications of tubulin.^{18, 19} One prominent
27 modification is the reversible removal of the C-terminal tyrosine residue of α -tubulin subunits,
28 which is exposed at the external surface of microtubules. This residue is cleaved off by specific
29 tubulin carboxy-peptidases, such as the recently identified Vasohibin 1 (VASH1) - Small
30 Vasohibin Binding Protein (SVBP) and Vasohibin 2 (VASH2)-SVBP complexes.²⁰⁻²² When
31 detyrosinated microtubules depolymerize, the tyrosine is rapidly restored on disassembled α -

1 tubulin by the enzyme tubulin tyrosine ligase, thereby replenishing the soluble tubulin pool with
2 full-length subunits that are then available for renewed polymerization.²³⁻²⁷ Due to these
3 sequential reactions, tubulin undergoes a continuous cycle of detyrosination and re-tyrosination.
4 Detyrosinated microtubules can be further processed by cytosolic carboxypeptidases of the
5 deglutamylase family to generate $\Delta 2$ and $\Delta 3$ tubulins through the sequential cleavage of the final
6 2 or 3 amino acids, respectively.²⁸⁻³¹ $\Delta 2$ tubulin cannot be re-tyrosinated by tubulin tyrosine
7 ligase, and is thus removed from the tyrosination/detyrosination cycle.^{27, 32} It follows that tubulin
8 tyrosine ligase suppression induces an accumulation of detyrosinated and $\Delta 2$ -tubulins, whereas
9 tubulin carboxypeptidase inhibition has the opposite effect.³³⁻³⁵

10 Newly formed tyrosinated microtubules are highly dynamic, contrary to detyrosinated
11 microtubules which are typically more stable.^{26, 36, 37} Indeed, while it is known that tubulin
12 detyrosination can occur on previously stabilized microtubules,^{38, 39} there is also evidence that
13 detyrosination of tubulin may itself promote microtubule stability by protecting microtubules
14 from the depolymerizing activity of kinesin-13 motors.⁴⁰ Thus, microtubule dynamics and the
15 tyrosination/detyrosination cycle are intertwined, and modulation of the cycle is critical to
16 processes in which microtubules need to maintain a specific dynamic state. Moreover,
17 microtubule detyrosination confers preferential binding for specific motors and other
18 microtubule-associated proteins, allowing tyrosination-dependent loading of selected cargoes
19 and microtubule modulators. For example, in neurons, detyrosinated microtubules play a unique
20 role in neuronal transport by acting as preferential tracks for kinesin-1 and kinesin-2,⁴¹⁻⁵⁰ while
21 inhibiting cytoplasmic linker proteins and dynein loading onto microtubule plus ends.^{33, 51}

22 Additional roles for detyrosinated microtubules as regulators of microtubule severing enzymes
23 have been suggested.^{52, 53} In neurons, these functions regulate the trafficking of cargoes, axon
24 outgrowth and branching. For example, kinesin-1 preferentially moves along detyrosinated
25 microtubules.⁵⁰ Kinesin-1 is involved in mitochondria trafficking,⁵⁴ targeting of α -amino-3-
26 hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to dendrites⁵⁵ and AMPA
27 receptor-mediated synaptic transmission.⁵⁶ Kinesin-1 may also regulate inhibitory transmission
28 by directing the transport of gamma aminobutyric acid (GABA) receptors via huntingtin-
29 associated protein 1.^{57, 58} Furthermore, robust kinesin-2 motility requires detyrosination of α -
30 tubulin⁴⁹ and homodimeric kinesin-2 has been implicated in the transport of glutamate receptors,

1 whereas disruption of kinesin-2 impaired LTP, LTD and cAMP response element-binding
2 protein responses in mice.⁵⁹

3 While the function of $\Delta 2$ tubulin remains unknown, it is very abundant in neurons where it
4 accumulates on very long-lived microtubules.³² Unbuffered accumulation of $\Delta 2$ tubulin,
5 however, has been recently associated with axonal degeneration that occurs following inhibition
6 of mitochondrial motility.³⁵ In the brain, significant alteration of the tyrosination/detyrosination
7 cycle during development modifies the relative ratio of tyrosinated, detyrosinated and $\Delta 2$ tubulin,
8 leading to severe neurodevelopmental phenotypes in mice.^{34, 60} SVBP knock-out in mice, which
9 lead to no activity of the tubulin carboxypeptidases VASH1 and VASH2, resulted in perturbed
10 neuronal migration in the developing neocortex, microcephaly and cognitive defects, including
11 mild hyperactivity, lower anxiety and impaired social behavior.³⁴ Similarly, biallelic inactivating
12 *Svbp* variants in human cause a syndrome involving brain anomalies with microcephaly,
13 intellectual disability and delayed gross motor and speech development.^{34, 61} Finally, *tubulin*
14 *tyrosine ligase* knock-out mice show disorganization of neocortical layers, disruption of the
15 cortico-thalamic loop, and death just after birth.^{60, 62} However, it remains unknown whether post-
16 developmental alteration of the tubulin tyrosination/detyrosination cycle plays a role in
17 neurodegenerative diseases.

18 Alzheimer's disease is an age-related, neurodegenerative disorder, defined by two main
19 pathological features: overabundance of amyloid beta peptide and hyperphosphorylated tau.⁶³
20 The most prominent clinical symptom is progressive memory loss, and decreases in synaptic
21 density are associated with cognitive impairment.^{64, 65} Alzheimer's disease is a multifactorial
22 disease, with both genetic and environmental etiologies.⁶⁶ The London (V717I) mutation in the
23 amyloid precursor protein (APP) is sufficient to cause early onset familial Alzheimer's disease⁶⁷
24 and elevated amounts of oligomeric amyloid β peptide (1-42) ($\alpha A\beta$),⁶⁸ a variant of amyloid β
25 peptide more likely to oligomerize⁶⁹ and to form disruptive plaques in the brain.⁷⁰

26 Recently, increased levels of modified tubulin (polyglutamylated and/or $\Delta 2$) have been found in
27 the hippocampi of postmortem patients with Alzheimer's disease, suggesting that defects in α -
28 tubulin retyrosination may be implicated in Alzheimer's disease.⁷¹ Interestingly, fluctuations of
29 detyrosinated tubulin in synaptosomal fractions from the dentate gyrus and corresponding
30 microtubule instability/stability phases have been associated with associative learning and
31 memory consolidation.¹⁷ In that study, aged mice failed to regulate learning-dependent

1 microtubule instability/stability phases and pharmacological disruption of either of the two
2 phases led to deficits in memory formation. These data indicate that failure in regulating the
3 tyrosination/detyrosination cycle occurs as a result of aging¹⁷ and may play a primary role in
4 synaptic plasticity and dementia related disorders. Moreover, oA β induces detyrosinated
5 microtubules in hippocampal neurons and this activity contributes to tau hyperphosphorylation
6 and tau dependent synaptotoxicity.⁷² Finally, loss of microtubule dynamics was also reported in
7 neurons from *Kif21b* knock-out mice that exhibit learning and memory disabilities.⁷³ Despite
8 these compelling evidences, whether perturbation of the tyrosination/detyrosination tubulin cycle
9 is a molecular driver of synaptic pathology remains unexplored.

10 We hypothesized that loss of tubulin retyrosination and consequential accumulation of
11 detyrosinated and $\Delta 2$ tubulins are molecular drivers of synaptic pathology by affecting
12 microtubule dynamics in spines. Indeed, we found that in the hippocampus of tubulin tyrosine
13 ligase hemizygous mice (TTL^{+/-}), reduced levels of tubulin tyrosine ligase expression led to
14 significant changes in the tyrosinated/detyrosinated tubulin ratio and produced defects in
15 synaptic transmission and plasticity that were associated with a loss of excitatory synapses. We
16 examined whether tubulin tyrosine ligase depletion was a *bona fide* feature of neurodegenerative
17 disease and found that tubulin tyrosine ligase was down-regulated in both sporadic and familial
18 Alzheimer disease, and that abnormally high levels of detyrosinated and $\Delta 2$ tubulins
19 accumulated in brain samples of Alzheimer's disease patients. We explored whether tubulin
20 tyrosine ligase and dynamic microtubules had a protective effect against the loss of synapses
21 induced by oA β . We found that microtubule entry into spines protected neurons from spine
22 pruning and that acute oA β exposure decreased the fraction of spines invaded by microtubules
23 prior to spine loss. Remarkably, tubulin tyrosine ligase expression inhibited both spine loss and
24 the decrease in the fraction of spines invaded by microtubules, underscoring a role for
25 retyrosinated tubulin in protecting synapses by driving dynamic microtubules into spines.

26 Our data unveil a role for the tyrosination/detyrosination tubulin cycle in regulating cognitive
27 parameters such as dendritic spine density, synaptic plasticity and memory. They also provide
28 compelling evidence for dysfunction of the cycle in Alzheimer's disease and suggest that
29 regulation of α -tubulin retyrosination may be critical for shielding synapses against oA β -induced
30 synaptic injury by promoting invasion of dynamic microtubules into spines.

31

1 **Materials and methods**

2 **Animals**

3 All experiments involving mice were conducted in accordance with the policy of the Institut des
4 Neurosciences de Grenoble (GIN) and in compliance with the French legislation and European Union
5 Directive of 22 September 2010 (2010/63/UE). Tubulin tyrosine ligase heterozygous mice (TTL^{+/-}) were
6 obtained as previously described⁶⁰ and maintained in a C57BL6 genetic background by recurrent back-
7 crosses with C57BL6 animals from Charles River Laboratories. Th1-eYFP line H mice⁷⁴ were obtained
8 from Jackson Labs (B6.Cg-Tgn (Thy-YFP-H) 2Jrs) and crossed with TTL^{+/-} mice to generate a colony of
9 C57BL6/Thy1-eYFP TTL mice. All experiments involving rats were approved by the Committee on the
10 Ethics of Animal Experiments of Columbia University and performed according to Guide for the Care and
11 Use of Laboratory Animals distributed by the National Institutes of Health. E18 pregnant Sprague
12 Dawley rats were purchased from Charles River Laboratories.

13 **Electrophysiology**

14 Electrophysiological tests were done with 3 and 9-month old wild-type (WT) and TTL^{+/-} mice.

15 **Ex vivo slice preparation** After cervical dislocation of the mice, brains were isolated and brain
16 slices prepared from WT and TTL^{+/-} male or female mice. The brain was removed quickly and 350 μ m
17 thick sagittal slices containing both cortex and hippocampus were cut in ice-cold sucrose solution (in
18 mM: KCl 2.5, NaH₂PO₄ 1.25, MgSO₄ 10, CaCl₂ 0.5, NaHCO₃ 26, Sucrose 234, and Glucose 11, saturated
19 with 95% O₂ and 5% CO₂) with a Leica VT1200 blade microtome (Leica Microsystems, Nanterre,
20 France). After the cutting, the hippocampus was extracted from the slice and transferred in oxygenated
21 artificial cerebrospinal fluid (ACSF) (in mM: NaCl 119, KCl 2.5, NaH₂PO₄ 1.25, MgSO₄ 1.3, CaCl₂ 2.5,
22 NaHCO₃ 26, and Glucose 11) at 37 \pm 1 °C for 30 minutes and then kept at room temperature for at least
23 1 hour before recordings.

24 **Electrophysiological recordings** Each slice was individually transferred to a submersion-type
25 recording chamber and continuously superfused (2 ml/minute) with oxygenated ACSF at 28°C.
26 Extracellular recordings were obtained from the apical dendritic layers of the hippocampal CA1 area,
27 using glass micropipettes filled with ACSF. Field excitatory postsynaptic potentials (fEPSPs) were evoked

1 by the electrical stimulation of Schaeffer collaterals afferent to CA1. The magnitude of the fEPSPs was
2 determined by measuring their slope. Signals were acquired using a double EPC 10 Amplifier (HEKA
3 Elektronik Dr. Schulze GmbH, Germany), recorded with Patchmaster software (HEKA Elektronik Dr.
4 Schulze GmbH, Germany) and analyzed with Fitmaster software (HEKA Elektronik Dr. Schulze GmbH,
5 Germany). Input/output (I/O) curves characterizing basal glutamatergic transmission at CA3-CA1
6 synapses of WT and TTL^{+/-} mice were constructed by plotting mean fEPSPs slopes \pm SEM as a function of
7 stimulation intensity (10 to 100 μ A). For LTP experiments test stimuli were delivered once every 15
8 seconds and the stimulus intensity was adjusted to produce 40-50% of the maximal response. LTP was
9 induced using a Theta Burst Stimulation (TBS involved 5 trains with 10 bursts of 4 pulses delivered at 100
10 Hz, an interburst interval of 200 milliseconds and 20 second interval between each train). Average value
11 of fEPSP slope was expressed as a percentage of the baseline response \pm SEM.

12 Behavioral studies

13 Behavioral tests were done in 3 to 4-month old WT and TTL^{+/-} mice. Evaluation of cognitive function was
14 performed with spontaneous alternation in the Y maze test for working memory, and with the Novel
15 Object Recognition test for episodic memory. Procedures were performed during the animals' light
16 cycle. For each test, animals were habituated to the test room for 30 minutes; room lighting was set to
17 150 Lux and ambient sound was provided by white noise generators set for 60 dB of white noise. Animal
18 testing order within a test was organized to prevent animals from being single housed immediately prior
19 to being tested. Experimenter was blinded to the genotype of animals during testing. Only males were
20 used.

21 **Spontaneous alternation test** was conducted in a Y-shaped maze, made of black Plexiglas. The
22 maze is heightened approximately 1 meter high, constituted by 3 arms of equivalent size (L = 38 cm; W =
23 8 cm; H of walls = 15 cm), numbered from 1 to 3, and by equivalent angles between them (120°). The
24 mouse was put in the center of the maze, the nose in the direction of the bottom of one of the arms.
25 The mouse was free to explore the environment for 5 minutes. The experimenter observed the behavior
26 by using a camera located in an independent room and noted the sequence of successive arm visits. A
27 visit or an entrance into an arm was defined as four legs in the zone of the arm. The apparatus was
28 cleaned with alcohol and subsequently with water between each mouse. An alternation is defined as a
29 visit in a given arm followed by a visit into the other arm. The successive sequence of visits during 5
30 minutes determines the level of alternation. The performance of the animal is estimated by calculating a

1 percentage of alternation: Alternation index = [number of alternations/ (total number of visited zones-
2 2)] x 100.

3 **Novel object recognition test** was performed in Y shaped maze, to about 1 meter in height,
4 consisting of three opaque black plastic arms of equal size (L = 38 cm, W = 8 cm, H of wall = 15 cm),
5 numbered 1 to 3, and at a 120° angle from each other. Four different objects by size, shape and pattern
6 were used. The recognition test had three phases: habituation, familiarization and recognition. For
7 habituation at day 1, the mouse was placed in the center of the Y-maze, without object, to freely
8 explore the three arms for 10 minutes. For familiarization at day 2, the mouse was again placed in the
9 center of the Y-maze which contained at each end different objects. The mouse freely explored for 5
10 minutes, during which it can familiarize with these three objects. For recognition test, 1 hour after
11 familiarization, the mouse was placed in the center of the Y-maze where one object presented during
12 the familiarization phase was replaced by a new object. The mouse freely explored for 5 minutes and
13 the experimenter measured the time of exploration of each object using a semi-automatic key. The
14 assessment criterion was the difference between the time of exploration of the new object and the
15 mean time of the time of exploration of the two familiar objects. Recognition index = difference [New
16 object – (Mean of the two familiar objects)] durations (in seconds) of exploration.

17 **Plasmids**

18 For lentiviral experiments, vector eGFP-pWPT (Addgene #12255, kind gift from D. Trono) was used to
19 express eGFP, and cDNA encoding human tubulin tyrosine ligase (NP_714923, Origene #RC207805L2)
20 was cloned in it for tubulin tyrosine ligase expression. PCR amplification and cloning of tubulin tyrosine
21 ligase cDNA was performed with Phusion DNA polymerase (Thermo Scientific) and In-Fusion HD Cloning
22 kit (Clontech), respectively. eGFP cDNA was removed during the cloning process to produce an untagged
23 tubulin tyrosine ligase. For lentiviral shRNA expression, 2 tubulin tyrosine ligase shRNA sequences,
24 cloned in pLKO.1 vector, were purchased from Sigma-Aldrich: shTTL1 (TRCN0000191515, sequence: 5' -
25 CCG GCA TTC AGA AA GAG TAC TCA ACT CGA GTT GAC TAC TCT TTC TGA ATG CTT TTT TG - 3') and
26 shTTL2 (TRCN0000191227, sequence: 5' - CCG GCT CAA AGA ACT ATG GGA AAT ACT CGA GTA TTT CCC
27 ATA GTT CTT TGA GTT TTT TG - 3')³⁵. The SHC001 pLKO.1-puro Empty Vector (Sigma) was used as
28 control (shControl). For the transfection experiments, the plasmid encoding pCMV-EB3-EGFP was a kind
29 gift from Dr. Frank Polleux.⁷² Kind gifts from Dr. Erik Dent include the plasmids EB3-tdTomato (Addgene
30 #50708) and the plasmid encoding DsRed2 (Clontech), cloned into a pCAX vector. The plasmid pEGFP-N1

1 with a CMV promoter was also used (Addgene #6085-1). All constructs were verified by sequencing
2 (Eurofins and Genewiz). Plasmids were purified with HiPure Plasmid Maxiprep kits (Invitrogen).

3 **Amyloid β peptide (1-42) oligomers preparation**

4 Oligomer-enriched preparations of amyloid β peptide (1-42) were obtained according to previously
5 published methods^{72, 75}. Briefly, the lyophilized amyloid β peptide (1-42) (rPeptide) was resuspended in
6 1,1,1,3,3,3-hexafluoro-2-propanol to a concentration of 1 mM and monomeric amyloid β peptide (1-42)
7 aliquots were resuspended in anhydrous dimethyl sulfoxide to 5 mM followed by vortexing and 10-
8 minute sonication. The resuspended peptide was diluted to 100 μ M in ice-cold Ham's F-12 medium and
9 incubated at 4°C for 24 hours before use.

10 **Lentivirus production**

11 Lentiviral particles were produced using the second-generation packaging system as previously
12 described.^{72, 75} Lentivirus encoding GFP or tubulin tyrosine ligase cDNA (packaging vectors, pWPT-based
13 vector, Addgene, Cambridge, MA) and shTTL1, shTTL2 and control shRNA (packaging vectors pLP1, pLP2,
14 and pLP-VSV-G, Thermofisher) were produced by co-transfection with the psPAX2 and pCMV-VSV-G
15 helper plasmids, into HEK293T cells obtained from ATCC (ATCC-CRL-3216) using the calcium phosphate
16 transfection method. Viral particles were collected 48 hours after transfection by ultra-speed
17 centrifugation, prior to aliquoting and storage at -80°C.

18 **Primary hippocampal neuronal cultures**

19 **Mouse hippocampi** (E18.5) were digested in 0.25% trypsin in Hanks' balanced salt solution (HBSS,
20 Invitrogen, France) at 37°C for 15 minutes. After manual dissociation, cells were plated at a
21 concentration of 5,000-15,000 cells/cm² on 1 mg/ml poly-L-lysine-coated coverslips for fixed samples, or
22 on ibidi glass bottom μ Dishes (35 mm) for live imaging. Neurons were incubated 2 hours in DMEM-10%
23 horse serum and then changed to MACS neuro medium (Miltenyl Biotec) with B27 supplement
24 (Invitrogen, France).

25 **Rat hippocampi** were dissected from E18 embryos, and neurons were plated on 100 μ g/ml poly-d-
26 lysine-coated 12-well plates at the density of 3×10^5 cells/well for biochemistry assays, 5×10^4 cells/dish
27 for live imaging in the chamber of 35-mm MatTek dishes or 4×10^4 cells/coverslip on 18-mm coverslips

1 for fixed samples. Primary neurons were maintained in Neurobasal medium (Invitrogen) with the
2 supplement of 2% B-27 (Invitrogen) and 0.5 mM glutamine (Invitrogen), and one third of medium was
3 changed every 3–4 days up to 4 weeks in culture.

4 **Lentivirus infection** To perform dendritic spine quantification, 1/100 of a hippocampal cell
5 suspension was infected by 15-minute incubation with GFP lentivirus (Lv) at a multiplicity of infection of
6 40. The infected population was then mixed with non-transduced cells before plating. Some of those
7 cultures were infected at 1 day *in vitro* (DIV) with tubulin tyrosine ligase lentivirus at a multiplicity of
8 infection of 5. Hippocampal neurons were incubated for 18 DIV at 37°C, 5% CO₂ in a humidified
9 incubator and then fixed with 4% paraformaldehyde in 4% sucrose-containing PBS for 20 minutes. To
10 induce acute tubulin tyrosine ligase reduction, hippocampal neurons from WT rat embryos were
11 infected at DIV 14 or DIV 17 with lentiviral vectors containing either control or 1 of 2 independent
12 tubulin tyrosine ligase-targeting shRNAs and incubated until DIV 21. Ectopic expression of tubulin
13 tyrosine ligase for microtubule spine dynamics experiments was also achieved through lentiviral
14 infection, with infection again occurring at DIV 14 and incubation until DIV 21.

15 **Imaging of dendritic spines**

16 For *in vivo* fixed samples, serial sections were obtained from cortical layer V of 3-month-old Thy1eYFP-H
17 WT and Thy1eYFP-H TTL^{+/-} male mice brains. Briefly, mice were anesthetized, perfused transcardially
18 with saline followed by 4% paraformaldehyde and brain recovered. For cultured samples, hippocampal
19 neurons from WT, TTL^{+/-} and TTL^{-/-} embryos were infected with eGFP containing lentivirus and fixed at
20 DIV 18. Dendritic segments visualized by soluble eYFP and eGFP respectively, were obtained using a
21 confocal laser scanning microscope (Zeiss, LSM 710). Serial optical sections (1024 × 1024 pixels) with
22 pixel dimensions of 0.083 × 0.083 μm were collected at 200 nm intervals, using a × 63 oil-immersion
23 objective (NA 1.4). The confocal stacks were then deconvolved with AutoDeblur. For *in vitro* analysis of
24 spines in cultured hippocampal neurons isolated from rat embryos and infected with tubulin tyrosine
25 ligase-targeting shRNAs, DiOlistic labeling using the Helios gene gun system (Bio-Rad) was performed
26 according to the manufacturer's instructions. Tungsten particles (1.1 μm, Bio-Rad) coated with Dil
27 (Invitrogen), which defines the neuronal architecture in red, were delivered into hippocampal neurons
28 fixed in 4% paraformaldehyde prior to mounting with ProLong Gold antifade mounting reagent
29 (Invitrogen). Neurons were imaged the next day using an Olympus IX8Andor Revolution XD Spinning Disk
30 Confocal System. Z stack images were taken at 0.2 μm step length for 10-15 stacks and shown as

1 maximum projections. Dendritic spine analysis (spine counting and shape classification) was performed
2 on the deconvolved stacks using Neuronstudio and Neurolucida 360.⁷⁶ All spine measurements were
3 performed in 3D from the z-stacks. The linear density was calculated by dividing the total number of
4 spines present on assayed dendritic segments by the total length of the segments. At least 3 dendritic
5 regions of interest were analyzed per cell from at least 3 independent cultures in each experimental
6 condition.

7 **Live imaging of microtubule dynamics at spines**

8 Rat neurons grown on 35 mm glass bottom live imaging dishes (MaTek) were co-transfected with
9 plasmids encoding either EB3-eGFP and DsRed or EB3-tdTomato and eGFP using Lipofectamine 2000
10 (Invitrogen). Live cell imaging was performed 24-48 hours after transfection in complete HBSS media
11 (HBSS, 30 mM glucose, 1 mM CaCl₂, 1 mM MgSO₄, 4 mM NaHCO₃, and 2.5 mM HEPES, pH 7.4) using an
12 IX83 Andor Revolution XD Spinning Disk Confocal System. The microscope was equipped with a
13 100×/1.49 oil UApo objective, a multi-axis stage controller (ASI MS-2000), and a controlled temperature
14 and CO₂ incubator. Movies were acquired with an Andor iXon Ultra EMCCD camera and Andor iQ 3.6.2
15 live cell imaging software. Movies of microtubule dynamics at spines were acquired at 4 seconds/frame
16 for 10 minutes with 3 z-stack planes at 0.4 μm step size. Maximum projections of movies were
17 performed by Image Math within Andor software, exported as Tiff files and analyzed in ImageJ.
18 Kymographs were generated by drawing a region from the base of the spine to the tip of spine head.
19 Parameters describing microtubule invading into spines were defined as follows: % of spines invaded 10
20 minute⁻¹: number of spines invaded by microtubules during 10-minute movie/total number of spines in
21 the imaging field; invasion lifetime: total duration of EB3 residing in a spine including comet lifetimes of
22 multiple invasions.¹⁰ Parameters describing microtubule dynamics were defined as follows:
23 rescue/nucleation frequency: number of rescue or nucleation events per μm² per minute; catastrophe
24 frequency: number of full tracks/total duration of growth; comet density: number of comets per μm²
25 per minute; growth length: comet movement length in μm; comet lifetime: duration of growth; growth
26 rate: growth length/comet lifetime.⁷⁷

27 **Analysis of spine structural plasticity**

28 Morphologies (stubby, mushroom, thin) of all protrusions invaded or not invaded by EB3 in the same
29 imaging field before (0 hours) and after vehicle or oAβ treatment (2 hours) were individually
30 documented using NeuronStudio Software. Percentages of the same protrusions changing to pruned,

1 thin, mushroom, or stubby spines were then calculated based on total number of spines invaded or not
2 invaded by EB3 in the same field. χ^2 tests were performed on spine persistence or pruning in vehicle and
3 oA β treated neurons at 0 and 2 hours. χ^2 tests were also performed on spine morphology changes (to
4 thin, to stubby, to mushroom, to pruned) in vehicle and oA β treated neurons at 0 and 2 hours.

5 **Biochemical analysis of post-mortem human brain tissues**

6 Human brains were provided by the Human Brain Tissue Bank, Semmelweis University, Budapest,
7 Hungary. Tissue samples consist of 4 regions of brain (entorhinal cortex, hippocampus, temporal and
8 lateral prefrontal cortex) coming from a panel of 29 male and female patients aged from 52 to 93 years:
9 11 controls, 5, 6 and 7 from each group corresponding to Braak stadium I-II, III-IV and IV-V (Table S1).

10 **Extraction** Brain samples were homogenized 2 x 30 seconds at room temperature in (10% vol / w) 10
11 mM Tris, 0.32 M sucrose, pH 7.4 containing complete inhibitors cocktail (Roche) using ready to use
12 Precellys Lysing Kit (Bertin Technologies) in a Minilys apparatus. After lysis, the homogenates were
13 collected, frozen in liquid nitrogen and then stored at -80°C until use. When needed, frozen aliquots
14 were diluted v/v with RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS,
15 pH=8) stirred 30 minutes at 4°C and then centrifuged 10 minutes at 14000 g at 4°C. Supernatants were
16 frozen in liquid nitrogen and then stored at -80°C until use.

17 **Antibodies** Monoclonal rat anti-tyr-tubulin (YL1/2), polyclonal anti detyrosinated, $\Delta 2$ tubulin
18 antibodies and monoclonal anti α tubulin antibody ($\alpha 3A1$) were produced in the Andrieux's lab as
19 previously described.³² Mouse monoclonal anti-tubulin tyrosine ligase antibody ID3 was as described⁷⁸
20 and polyclonal antibody 13618-1-AP was purchased from Proteintech.

21 **Western blot analysis and quantification** RIPA supernatants (10 μ l) were subjected to
22 electrophoresis on stain free 4%-15% gels (Bio Rad) and then quickly transferred to Nitrocellulose using
23 Trans-Blot Turbo Transfer System (Bio Rad). Proteins on the membrane were revealed using specific
24 antibodies against different forms of modified tubulin (tyrosinated, detyrosinated, $\Delta 2$) and α tubulin.
25 Anti Tyr-Tub (1/10000), anti deTyr-Tub (1/20000), anti $\Delta 2$ -Tub (1/20000) and anti α tubulin (1/10000)
26 antibodies were used with the appropriate peroxidase-/labeled secondary antibodies. Secondary
27 antibody signal was revealed using Pierce ECL Western blotting substrate (Thermo scientific) and
28 analyzed with ChemiDoc™MP Imaging System (Bio Rad) using Image Lab software (stain free gel

1 protocol) for quantification. For each lane of the blot, the software measures the integrated volume of
2 the band corresponding to the antigen of interest. The signal is then normalized according to the total
3 protein measured in the same lane. For every blot, one lane is dedicated to an internal standard
4 corresponding to a WT sample (used for the entire study) and the protein-normalized signal of this
5 standard is considered as 100%, therefore each unknown sample is calculated as a % of this standard.
6 For each brain sample, 3 independent blots were performed and the mean intensity was calculated.

7 **ELISA** The assay was routinely performed in high binding 96-well plates (Immulon 4 HBX, Thermo
8 Fisher). Washings throughout the assay were: 200 μ l/well, three times per washing step with Phosphate
9 Buffer Saline (PBS) buffer solution containing 0.05% Tween 20 (PBST). Anti-tubulin tyrosine ligase
10 antibody ID3 was coated at 1/2000 in PBS (100 μ l/well) overnight (\sim 16 hours) at 4 $^{\circ}$ C. After washing, the
11 plates were blocked by adding 2% Bovine Serum Albumin (BSA) in PBS (200 μ l/well) for 6 h at room
12 temperature. The plates were then washed and incubated overnight (\sim 16 h) at 4 $^{\circ}$ C with tubulin
13 tyrosine ligase standards or brain samples diluted in 1% BSA in PBS (100 μ l/well). The sample diluent
14 served as negative control. Washed plates were then incubated for 1 hour at room temperature with
15 anti-tubulin tyrosine ligase antibody (13618-1-AP) at 1/2000 in 1% BSA in PBST (100 μ l/well). Washed
16 plates were incubated for 1 hour at room temperature with peroxidase rabbit antibody diluted 1:10000
17 in BSA/PBST (100 μ l/well). The plates were washed and incubated with 3,3',5,5'-tetramethylbenzidine
18 Liquid Substrate (Sigma-Aldrich) (100 μ l/well). Reaction was stopped after 5 minutes by adding Stop
19 Reagent (Sigma-Aldrich) (100 μ l/well). Absorption was determined at 450 nm on Pherastar FS (BMG
20 Labtech). For each brain sample, 3 independent ELISA were performed and the mean value was
21 calculated. Purified tubulin tyrosine ligase was used for normalization (kind gift of M Steinmetz)²⁷.

22 **Biochemical analysis of cultured primary neurons**

23 Cortical neurons (17 DIV) isolated from mouse embryos were transduced or not with a lentivirus
24 expressing tubulin tyrosine ligase and treated with DMSO or with 100 nM oA β (48 h) prior to collection,
25 washing with phosphate-buffered saline medium at 37 $^{\circ}$ C and lysis in Laemmli buffer. The protein
26 contents of tubulin tyrosine ligase, tyrosinated and detyrosinated tubulin were analyzed by quantitative
27 western blot with the protocol used for human brain samples as described above. Several neuronal
28 cultures were used as indicated in figure legends and for each sample, 3 independent blots were
29 performed.

1 **Biochemical analysis of mouse brain tissues**

2 Mice hippocampi were homogenized in a lysis buffer (phosphate buffer saline (PBS) without CaCl₂ and
3 MgCl₂, 14190-094 Life Technologies) supplemented with protease (P8340, Sigma) and phosphatase
4 inhibitor cocktails (P5726 and P0044, Sigma) at 150 mg/mL, using a Precellys apparatus homogenizer (2
5 x 20 seconds, 5000 rpm). Lysates were then centrifuged at 21,000 *g* for 20 minutes at 4°C. The resulting
6 supernatants were collected and protein concentrations were determined using bicinchoninic acid
7 assays (Pierce/Thermo Fisher Scientific). Samples were stored at -80°C until analysis.

8 **Automated western blotting** was performed with equal concentrations of protein per sample
9 (0.125 µg/µL) using Peggy Sue™ system (Protein Simple, San Jose, CA, USA) according to the
10 manufacturer's instructions. Detection of tyrosinated, detyrosinated tubulins and tubulin tyrosine ligase
11 levels were assessed using appropriate primary antibodies as detailed above for human samples. Data
12 were analyzed with Compass software (Protein Simple).

13 **Immunohistochemical analysis of *post-mortem* brain tissues**

14 De-identified human autopsy brain tissue was obtained from the New York Brain Bank at Columbia
15 University (New York, NY, USA). Neuropathologically-confirmed Alzheimer's disease cases and controls
16 were processed following published protocols.⁷⁹

17 **Antibodies** Anti-Δ2 tubulin (AB3203) was from Millipore, anti detyrosinated tubulin (MAB5566) from
18 Sigma Aldrich and anti tau AT8 (MN1020) from Invitrogen.

19 **Immunolabelling** brain paraffin blocks were cut into 5 µm sections and deparaffinized in xylene (7
20 minutes twice) followed by 95% EtOH, 90% EtOH, 80% EtOH and 70% EtOH (5 minutes each). After
21 washing the slices in distilled H₂O 3 times, citric acid was used to retrieve antigen by boiling samples for
22 15 minutes. Sections were cooled for 15 minutes, washed 3 times with PBS and blocked with serum for
23 1 hour at room temperature prior to staining with primary antibodies (anti-detyrosinated tubulin, 1/100;
24 anti Δ2 tubulin 1/500 and AT8 anti Tau, 1/500) at 4°C overnight. The next morning sections were
25 washed 3 times with PBS and stained with appropriate secondary antibodies (Cy3 donkey anti mouse,
26 1/200; Alexa 488 donkey anti rabbit, 1/200; DAPI, 1/1000) for 1 hour at room temperature. Stained
27 samples were washed 3 times with PBS and incubated in 0.1% black Sudan in 70% EtOH for 5 minutes to

1 reduce auto-fluorescence of lipofuscin, rinsed with 70% EtOH until black was gone and rehydrated in
2 distilled H₂O.

3 **Image acquisition and analyses** Coverslips were mounted with Fluoromount prior to imaging
4 using an Olympus VS-ASW FL 2.7(Build 11032) slide scanner and Olympus soft imaging solutions camera
5 XM10. Images were taken using a 10x objective and same exposure time was used for the same primary
6 antibody (detyrosinated tubulin: 100 milliseconds; $\Delta 2$: 200 milliseconds; AT8 tau: 10 milliseconds; 4',6-
7 diamidino-2-phenylindole: 10 milliseconds). The images were converted into Tiff files for analysis using
8 MetaMorph software. Pyramidal neuron cell bodies and proximal dendrites were randomly selected in
9 the anterior hippocampal formation and average fluorescence intensity was measured for detyrosinated
10 and $\Delta 2$ tubulins, as well as for AT8. An average of 150 neurons were selected for each case. Pyramidal
11 neurons were arbitrarily classified into low AT8 (1-300 A.U.), intermediate AT8 (300.01-1000 A.U.) and
12 high AT8 (1000.01-2400 A.U.) based on AT8 staining intensity in the cell body.

13 **Mutant APP and isogenic control iPSC cell maintenance and** 14 **differentiation**

15 Human induced pluripotent stem cells (iPSCs) in which the APPV717I (London) mutation was knocked
16 into one allele of the control IMR90 cl.4 iPSC line (WiCell)⁸⁰⁻⁸² using CRISPR/Cas9 was generated by Dr.
17 Andrew Sproul's lab, as has been described previously.⁸³

18 **Maintenance** APPLon knockin (cl. 88) and the isogenic parent line were maintained feeder-free in
19 StemFlex media (Life) and Cultrex substrate (Biotechne).

20 **Neuronal differentiation** bankable neural progenitors were first generated using manual rosette
21 selection and maintained on Matrigel (Corning) as has been described previously.^{83, 84} Terminal
22 differentiations were carried out by plating 165,000 - 185,000 NPCs per 12 well plate in N2/B27 media
23 (DMEM/F12 base) supplemented with brain-derived neurotrophic factor (20 ng/ml; Biotechne) and
24 laminin (1 μ g/ml; Biotechne) on PEI (0.1%; Sigma) / laminin (20 μ g/mL)-coated plates. After 1 week of
25 differentiation, 100 nM Cytosine β -D-arabinofuranoside hydrochloride (Sigma) was added to reduce
26 proliferation of remaining neural progenitors.⁸⁴ A similar strategy was used for imaging plates (MaTek
27 Lifesciences). Differentiations were analyzed 30-40 days post plating. For later passage of neural
28 progenitors, we employed a CD271-/CD133+/CD184+ (Biolegend) flow-cytometry purification strategy

1 to remove minority neural crest contaminants (CD271+) that can expand over time, as previously
2 done.⁸⁵

3 **Western blot analyses of reprogrammed cortical neurons** Cell lysates from WT and
4 mutant human cortical neurons at 30-40 days of differentiation were lysed in Laemmli sample buffer
5 and boiled at 96°C for 5 minutes. Cell lysates were sonicated by probe sonication to shear cellular debris
6 and genomic DNA. Proteins were separated by 10% Bis-Tris gel (Invitrogen) and transferred to
7 nitrocellulose membrane. After blocking in 5% milk/TBS or BSA/TBS, membranes were incubated with
8 primary antibodies (anti total tau (tau 46) (sc-32274) from Santa Cruz; anti tau AT8 (MN1020) and anti-
9 GAPDH (MA5-15738 and PA5-85074) from Invitrogen; anti tubulin tyrosine ligase (13618-1-AP) from
10 Proteintech; anti detyrosinated tubulin (MAB5566) from Sigma Aldrich; Anti- $\Delta 2$ antibody (AB3203) from
11 Millipore) at 4°C overnight and 1 hour with appropriate secondary antibodies (LI-COR Biosciences).
12 Image acquisition was performed with an Odyssey infrared imaging system (LI-COR Biosciences) and
13 analyzed with Odyssey software.

14 **Statistical analysis**

15 Data analyses, statistical comparisons, and graphs were generated using GraphPad prism or the R
16 programming language. Statistical analysis of differences between two groups was performed
17 using Student's t tests for populations with Gaussian distribution or else with Mann Whitney's
18 test. When comparing 3 or more univariate samples we used one-way ANOVA, except for
19 Figures 2F, S4 and S6 in which we used the non-parametric Kruskal-Wallis test due to non-
20 normality of the samples. When ANOVA indicated that the factor under study had a significant
21 effect, post hoc comparisons between factor levels (using the unexplained variance calculated in
22 the ANOVA) were performed with the Dunnett or Sidak tests, depending on whether
23 comparisons were, respectively, with the sole control condition or between any two conditions.
24 Post-hoc comparisons following Kruskal-Wallis test were done with the non-parametric Dunn
25 test. For bivariate statistics we used two-way ANOVA, with type II sum of squares when
26 samples were unbalanced (to avoid confusion between factors). Post hoc comparisons were
27 performed between non-weighted marginal means, using Dunnett or Sidak tests, depending on
28 whether all-vs-control or all-vs-all comparisons were needed. The calculations were performed
29 with the R *car* and *emmeans* packages. For Fig 3B-F, as regular two-way ANOVA was not
30 suitable we used a linear mixed model and calculation of model coefficients by restricted

1 maximum likelihood estimation (using the R *lmer* package). The significance of fixed effects
2 (Braak stage and brain region) was then evaluated by Wald type II F tests (with Kenward-Roger
3 correction) of the null hypothesis for each of the model coefficients. Post hoc comparisons were
4 run by Sidak tests. In Fig 3H, to determine whether the distributions of immunoreactivity values
5 in control and Alzheimer's disease neuronal populations were significantly different we used the
6 Kolmogorov-Smirnov test. In Fig 5E, we used an overall chi-square test that showed that the
7 proportion of pruned spines significantly depended on at least one of the two factors under study
8 (oA β treatment and microtubule invasion). Then to evaluate the specific association of spine
9 resistance with microtubule entry, we calculated the odds ratio of spine pruning in vehicle versus
10 oA β -treated neurons, separately for microtubule-invaded and non-invaded spines. The
11 significance of the difference between the two odds ratios was assessed with the Woolf-test of
12 homogeneity of odds Ratios, using the R *vcd* package. In Fig S5B-C an overall chi-square test
13 was used on two factors under study (oA β treatment and microtubule invasion) and the 4
14 possible spines morphological fates. Mean differences were considered significant at $p < 0.05$ (*
15 $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ and **** $p < 0.0001$). Some exact p values are indicated in
16 text or figures.

17 **Data availability**

18 The datasets generated and/or analysed during the current study are available from the corresponding
19 authors on request.

20 **RESULTS**

21 **Inhibition of tubulin retyrosination induces age-dependent synaptic** 22 **defects**

23 Dynamic microtubules are crucial for synaptic plasticity and known to bear tyrosinated tubulin,
24 and so we directly examined whether perturbation of the tubulin tyrosination/detyrosination
25 cycle (Figure 1A) affects synaptic function. As total genetic ablation of tubulin tyrosine ligase is
26 perinatally lethal in mice,⁶⁰ we used TTL^{+/-} mice which are viable and fertile. Firstly, we
27 confirmed that in protein extracts from hippocampi of 3 and 9-month-old TTL^{+/-} mice both
28 tubulin tyrosine ligase protein levels and tyrosinated/detyrosinated tubulin ratio were
29 significantly reduced compared to WT mice (TTL^{+/-} = -44,95 \pm 3,95 % and -48.94 \pm 2.61 % of

1 WT and tyrosinated/detyrosinated tubulin ratio = -39.46 ± 5.04 % and -37.08 ± 4.71 % of WT
2 for 3 and 9-month-old mice respectively, Figure 1B-C and Supplementary Fig. 1A-C).

3 We performed spontaneous alternation in Y-maze and novel object recognition memory tests
4 (Figure 1D, E). These memory tests were selected because they broadly assess function of
5 cognitive domains that correlate with neural circuitry disrupted early in Alzheimer's disease,
6 including the hippocampus,⁸⁶ and have been useful to reveal memory defects in preclinical
7 models of β -amyloidosis and tauopathy.^{87, 88} $TTL^{+/-}$ mice exhibited robust deficits in spontaneous
8 alternation in Y-Maze (20.36 ± 0.91 versus 25.50 ± 1.09 number of entries and 68.44 ± 2.13
9 versus 51.88 ± 2.29 % of alternation for WT and $TTL^{+/-}$ mice, respectively) (Figure 1D). Also, in
10 the novel object recognition test, $TTL^{+/-}$ mice spent significantly less time exploring the novel
11 object than WT mice (delta between new and familiar object of 3.17 ± 0.33 versus 1.08 ± 0.37
12 sec for WT and $TTL^{+/-}$ mice, respectively) (Figure 1E). $TTL^{+/-}$ mice showed no defect in
13 locomotor activities and sensorimotor functions as well as intact hippocampus-dependent spatial
14 memory when assessed by the Morris Water Maze Test, consistently with lack of manifested
15 spatial navigation defects in most preclinical Alzheimer's disease models at a young age⁸⁹
16 (Supplementary Fig. 2). These data demonstrate that reduced tyrosinated/detyrosinated tubulin
17 ratio impairs spatial working and short-term recognition memory with negligible effects on
18 sensorimotor circuit development, hyperactivity and spatial navigation, a behavioral profile that
19 is compatible with the cognitive decline observed in preclinical models of Alzheimer's disease⁸⁶⁻
20 ⁸⁹.

21 Next, we investigated hippocampal synaptic transmission in 3 and 9-month-old WT and tubulin
22 tyrosine ligase hemizygous mice. The efficacy of basal excitatory synaptic transmission was
23 determined by field recordings of postsynaptic excitatory responses elicited by a range of
24 electrical stimuli of axonal CA3-CA1 Schaffer collateral fibers, in hippocampal slices. While in
25 3-month-old animals, the input/output (I/O) curves revealed no differences between genotypes,
26 in 9-month old mice, observed a significantly weaker postsynaptic response in $TTL^{+/-}$ than in
27 WT animals (Figure 1F, I) indicating defective basal synaptic transmission in older $TTL^{+/-}$ mice.
28 Furthermore, application of a theta-burst LTP protocol showed no difference in potentiation at 3-
29 month-old mice between WT and $TTL^{+/-}$ mice (Figure 1 G-H), but a reduced potentiation in 9-
30 month-old $TTL^{+/-}$ compared to WT mice (Figure 1 J-K, -25.04 ± 3.68 % of WT).

1 Altogether, these data demonstrate that a reduction in tubulin tyrosine ligase expression results in
2 loss of tyrosinated tubulin *in vivo*, early memory defects and age-dependent hippocampal
3 synaptic dysfunction that affects both basal transmission and activity-dependent plasticity.

4 **Inhibition of tubulin retyrosination affects dendritic spine density**

5 We examined the effects of tubulin tyrosine ligase reduction at the level of individual neurons by
6 measuring dendritic spine density and morphology both *in vivo* and using neurons in primary
7 neuronal culture. Dendritic spines are often classified in three morphological types,
8 corresponding to successive developmental stages: thin, stubby and mushroom-like spines.⁹⁰ For
9 *in vivo* evaluation, TTL^{+/-} mice were crossed with Thy1-e-YFP-H transgenic mice to visualize
10 dendritic spines, and spine density evaluated in layer V cortical neurons.⁷⁴ These neurons YFP
11 levels, allowing accurate quantification of spine density (Figure 2 A), in contrast to hippocampal
12 neurons in which expression levels were too high for proper assessment. Confocal microscopy of
13 *in situ* cortical neurons from TTL^{+/-}-Thy1-eYFP-H mice showed a 15.97 ± 2.6 % decrease in
14 dendritic spine density compared to WT^{+/-}-Thy1-eYFP-H littermates (2.147 ± 0.07 and $1.804 \pm$
15 0.05 spines/ μm for WT and TTL^{+/-}, respectively). The decrease mainly affected mature forms of
16 dendritic spines (Figure 2 A-B). A comparable drop in mature spines (-15.53 ± 1.2 % of WT)
17 was observed in cultured hippocampal neurons obtained from TTL^{+/-} embryos (1.204 ± 0.021
18 and 1.017 ± 0.014 spines/ μm for WT and TTL^{+/-}, respectively, Figure 2 C-D). Similar results
19 were obtained when acute tubulin tyrosine ligase knock-down was performed in rat hippocampal
20 neurons using two independent tubulin tyrosine ligase-targeting shRNAs (Figure 2E,
21 Supplementary Fig. 1D, F). Tubulin tyrosine ligase silencing resulted in an accumulation of $\Delta 2$
22 tubulin (Supplementary Fig. 1E, G) and induced a dramatic reduction of dendritic spine density
23 (Figure 2E-F, -52.88 ± 2.67 %; -47.14 ± 4.30 % of WT for shRNA1, shRNA2 treated neurons
24 respectively) with values similar to those observed in tubulin tyrosine ligase knock-out neurons
25 (Supplementary Fig. 3, -41.17 ± 1.25 % of WT for tubulin tyrosine ligase knock-out neurons).

26 Together, these results show that reducing tubulin tyrosine ligase expression affects the density
27 of dendritic spines *in vitro* and *in vivo*, providing evidence for a novel role for tubulin
28 retyrosination in regulating structural plasticity.

29

1 **Tubulin retyrosination is perturbed in Alzheimer's disease**

2 The synaptic and behavioral defects observed when levels of tyrosinated tubulin are perturbed
3 raised the question as to whether dysregulation of tubulin retyrosination is a feature of
4 Alzheimer's disease, a neurodegenerative disorder in which synaptic pathology is prominent at
5 early stages. We performed a detailed analysis of the relative amount of tubulin tyrosine ligase,
6 tyrosinated, detyrosinated and $\Delta 2$ tubulins in postmortem human brain tissues from sporadic
7 Alzheimer's disease patients and age-matched controls using enzymatic linked immunoassay
8 (ELISA) and immunoblots. For these analyses, each Alzheimer's disease brain was
9 histologically analyzed according to Braak's criteria⁹¹ to discriminate early (Braak I-II), middle
10 (Braak III-IV) and late Alzheimer's disease stages (Braak V-VI), as shown in Supplementary
11 Table 1. Alzheimer's disease sequentially affects the entorhinal cortex (E), hippocampus (H),
12 temporal cortex (T) and lateral prefrontal cortex (L). We analyzed tubulin tyrosine ligase levels
13 and the different α -tubulin forms in protein extracts prepared from these four brain regions of
14 Alzheimer's disease patients and controls (Figure 3A-F). Global analysis indicated a statistically
15 significant effect of Braak stages on tubulin tyrosine ligase content ($F(3, 25) = 4.3454$, $*p =$
16 0.0135 , Figure 3B, grey box). Post-hoc comparison of tubulin tyrosine ligase content in control
17 and Alzheimer's disease brains showed a significant decrease in temporal and lateral prefrontal
18 cortex of Alzheimer's disease patients ($\# p = 0.0322$ and $\# p = 0.012$, respectively for Braak V-VI
19 versus controls, Figure 3B). No significant effect of brain region on tubulin tyrosine ligase
20 content was observed ($F(3, 75) = 0.2185$, $p = 0.8833$, Figure 3B, grey box) suggesting that the
21 tubulin tyrosine ligase decrease observed in Alzheimer's disease samples affects the whole brain.
22 Regarding tyrosinated tubulin levels, a global analysis indicated that there was no significant
23 dependence on Braak stage ($F(3, 25) = 1.1336$, $p = 0.3556$, Figure 3C, grey box). For
24 detyrosinated and $\Delta 2$ tubulin levels, the Braak stage had a global significant effect ($F(3, 25) =$
25 3.515 , $*p = 0.0297$ and $F(3, 25) = 5.877$, $**p = 0.0035$ for detyrosinated and $\Delta 2$ tubulins,
26 respectively, Figure 3D-E, grey boxes). Post-hoc comparisons in each brain region as a function
27 of Braak stage, indicated that the detyrosinated tubulin content significantly accumulated in the
28 hippocampus of patients with advanced disease (Figure 3D, $\# p = 0.0131$ for Braak V-VI versus
29 controls). Further, the amount of $\Delta 2$ tubulin increased in all regions in Alzheimer's disease
30 samples, as compared to controls (Figure 3E, $\#\# p = 0.0018$, $p = 0.0584$, $\# p = 0.0195$ and $\# p =$
31 0.0144 for entorhinal, hippocampus, temporal and lateral cortex, respectively, for Braak V-VI

1 versus controls). Importantly, the amount of total tubulin did not vary with disease stage (F
2 $(3,25) = 1.54, p = 0.23$, Figure 3F), confirming that the increase observed in disease samples was
3 selective for detyrosinated and $\Delta 2$ tubulins. To note, the levels of tyrosinated, detyrosinated and
4 $\Delta 2$ tubulins, as well as total tubulin, were significantly different among brain regions (Figure 3C-
5 F grey boxes, ($F(3, 75) = 3.1183, *p = 0.0310$; $F(3, 75) = 8.190, ****p = 0.00008$; $F(3, 75) =$
6 $10.091, ****p = 0.00001$; $F(3, 75) = 6.19, ****p = 0.0008$ for tyrosinated, detyrosinated, $\Delta 2$ and
7 total tubulin, respectively), a feature mostly attributable to larger concentration of tubulin in the
8 entorhinal cortex extracts than in the other brain region samples.

9 Altogether, these results indicate that in Alzheimer's disease, a global tubulin tyrosine ligase
10 impairment is present from an early stage of the neurodegeneration process and is associated
11 with increased amounts of non-tyrosinated tubulin.

12 We next analyzed modifications in non-tyrosinated tubulin content *in situ* by performing an
13 immunocytochemistry study of Alzheimer's disease brains. We performed a semi-quantitative
14 immunofluorescence analysis of cell bodies and proximal dendrites of randomly selected
15 individual pyramidal cells in the anterior hippocampal formation of sections from Alzheimer's
16 disease and control tissue (Supplementary Table 2, Figure 3G-I). Each selected neuron was
17 classified for tau pathology with either low, intermediate or high level of AT8 labelling (Ser202
18 and Thr205 phospho-tau antibody) and the mean intensity of detyrosinated and $\Delta 2$ tubulin
19 staining was calculated. As expected, strongly AT8-reactive neurons were far more frequent in
20 the Alzheimer's disease samples, consistent with the pathological scoring of control and
21 Alzheimer's disease post-mortem human brains (Figure 3G-H, Supplementary Table 2).
22 Interestingly, we found that Alzheimer's disease neurons with relatively low levels of phospho-
23 tau, and thus presumably at an early stage of the degeneration process, were significantly
24 enriched in detyrosinated and $\Delta 2$ tubulins compared to non-diseased neurons (Figure 3I, **** p
25 < 0.0001 for each). In contrast, Alzheimer's disease neurons with intermediate AT8 staining still
26 displayed significant enrichment in $\Delta 2$ tubulin compared to non-diseased neurons (Figure 3I,
27 **** $p < 0.0001$) but a lower level of detyrosinated tubulin, presumably as a result of advanced
28 neurodegeneration and/or accelerated conversion of detyrosinated to $\Delta 2$ tubulin in diseased
29 brains. These *in situ* results confirmed the accumulation of non-tyrosinated tubulin in pyramidal
30 neurons in Alzheimer's disease and indicated that it may occur at an early stage of the
31 neurodegeneration process.

1 To explore whether perturbation of tubulin re-tyrosination and microtubule dynamics was a
2 hallmark of familial Alzheimer's disease, we utilized isogenic human iPSC lines in which the
3 Alzheimer's disease-linked London mutation (V717I) was knocked-in via CRISPR/Cas9 into
4 one allele of the APP gene to replicate the genuine familial Alzheimer's disease genotype.⁸³
5 Human iPSCs harboring the London mutation and the isogenic control parent line were
6 differentiated *in vitro* into human cortical neurons via a neural progenitor intermediate as
7 previously described.^{83, 84} After 30 to 40 days of differentiation, a time at which differentiated
8 cortical neurons establish synapses, neurons were lysed, and tubulin tyrosine ligase,
9 detyrosinated and $\Delta 2$ tubulin levels analyzed by immunoblotting. At this stage of differentiation,
10 the mutant neurons accumulated tau protein, which was hyperphosphorylated (tau46 and AT8,
11 Figure 4A-B), confirming the occurrence of a previously described pathological feature
12 associated with this APP mutation.⁶⁸ Consistent with our observations of brain samples, neurons
13 with mutant APP displayed a significant reduction in tubulin tyrosine ligase content (Figure 4C),
14 an increase in $\Delta 2$ tubulin levels, and showed a trend in the accumulation of detyrosinated tubulin
15 compared to isogenic controls (Figure 4D-E).

16 We next directly examined microtubule dynamics in human neurons by transiently expressing
17 the microtubule plus-end binding protein, EB3-eGFP to track the dynamic behavior of
18 microtubule plus ends (Figure 4F-L). We found that in neurons with mutant APP, while comet
19 density, growth rate and rescue/nucleation frequency were unchanged (Figure 4G, I, L),
20 catastrophe frequency (Figure 4H) was significantly reduced compared to WT controls with a
21 corresponding increase in comet lifetime and length of growth (Figure 4J, K). These
22 observations are consistent with mutant APP-dependent inhibition of microtubule dynamics by
23 inducing resistance to undergo microtubule depolymerization.

24 Together, our results indicate that tubulin re-tyrosination is affected in sporadic and familial
25 Alzheimer's disease and that inhibition of microtubule dynamics observed in mutant APP human
26 neurons is consistent with a disrupted tubulin tyrosination/detyrosination cycle.

27 **Tubulin retyrosination protects neurons from oA β synaptotoxicity** 28 **and promotes microtubule invasion into spines**

29 APP variants such as the London mutant generate larger amounts of amyloid β peptide (1-42)⁹² and
30 soluble oA β has been proposed to contribute to loss of synapses at an early stage of neurodegeneration
31 in Alzheimer's disease.⁹³ We analyzed the consequences of oA β on the behavior of spine invading

1 microtubules in cultured hippocampal neurons. First, we observed that neurons exposed to oA β lost
2 their spines in a time-dependent manner (-6.80 ± 4.63 %, -19.56 ± 4.41 %; -36.42 ± 2.79 % and $-40.33 \pm$
3 6.57 % of control cells after 1, 2, 3 and 6 hours of oA β exposure, respectively) (Figure 5A-B). Next, we
4 analyzed the dynamics of microtubule invading into individual spines of neurons co-transfected with
5 plasmids expressing EB3-eGFP and DsRed as a cell filler, in response to oA β (Figure 5C). The dynamic
6 parameters of spine-invading microtubules (length of growth, comet lifetime, growth rate) and spine
7 invasion lifetime were not affected by oA β (Supplementary Fig. 4). However, oA β acutely inhibited
8 microtubule entry into spines at 0.5 hours, while inducing a time-dependent renormalization of the
9 fraction of microtubule-invaded spines starting at 2 hours (3.68 ± 0.21 %, 1.03 ± 0.29 %, 5.58 ± 0.54 %,
10 4.97 ± 0.48 % and 4.70 ± 0.77 % of spines for 0, 0.5, 2, 3 and 6 hours of treatment respectively, Figure
11 5D), an effect possibly due to the reduction of the total number of spines over time (Figure 5B). We
12 tracked and quantified the morphology of the same spines invaded or not invaded by microtubules in
13 neurons treated with vehicle or oA β for 2 hours (Figure 5E). In the absence of oA β , microtubule-invaded
14 thin spines appeared to switch more frequently to the larger stubby and mushroom spine types
15 (Supplementary Fig. 5), a phenotype in agreement with previous observations reporting modifications of
16 spine morphology upon microtubule entry.¹¹ However, in the presence of oA β , spines that were not
17 invaded by dynamic microtubules had a higher chance of being pruned (Figure 5E and Supplementary
18 Fig. 5B-C) and the non-invaded mushroom spines that did not collapse showed increased transitions to
19 stubby or thin spines, presumably causing additional loss of synaptic strength (Supplementary Fig. 5B-C).
20 For example, after 2 hours of oA β treatment, only 9 % of microtubule-invaded spines were pruned
21 compared to 35 % of non-targeted spines (Figure 5E).

22 These results indicate that oA β causes early inhibition of microtubule entry into spines, and that
23 these changes may be functionally related to the onset of spine pruning. The renormalization of
24 the percentage of microtubule-invaded spines that we observed at later time points might thus
25 reflect a relative accumulation of a class of spines which are intrinsically resistant to pruning.

26 These results further suggest that entry of dynamic microtubules, which are mainly composed of
27 tyrosinated tubulin, may underlie the resistance of dendritic spines to synaptic injury by oA β .

28 We next examined the effect of chronic exposure to oA β on tubulin tyrosine ligase and tubulin
29 tyrosination levels in primary cultured neurons. We found that 2 days of chronic 100 nM oA β
30 exposure resulted in a 25.77 ± 5.23 % reduction in tubulin tyrosine ligase content (Figure 6A),
31 similarly to what we observed in sporadic and familial Alzheimer's disease samples (Figure 3B

1 and Figure 4A, C). Acute 250 nM $\text{oA}\beta$ exposure resulted in a decline of both tubulin tyrosine
2 ligase levels and the tyrosinated/detyrosinated tubulin ratio starting at 30 minutes
3 (Supplementary Fig. 6), a timepoint at which microtubule entry into spines was inhibited.
4 Lentivirus-driven tubulin tyrosine ligase expression in these samples was performed to an extent
5 that did not significantly affect tyrosinated/detyrosinated tubulin ratio nor spine density in
6 control neurons (Figure 6A-C), and we then tested for $\text{oA}\beta$ -induced spine pruning. Strikingly, in
7 tubulin tyrosine ligase-expressing neurons, $\text{oA}\beta$ completely failed to diminish spine density
8 (Figure 6C-D), indicating that spine loss induced by $\text{oA}\beta$ might rely on downregulation of
9 tubulin tyrosine ligase and tyrosinated tubulin levels. Global biochemical analysis showed that
10 100 nM $\text{oA}\beta$ did not appreciably alter the proportion of tyrosinated tubulin in these neurons
11 (Figure 6B). However, it was conceivable that $\text{oA}\beta$ might have locally affected the pool of
12 tyrosinated, dynamic microtubules available for spine entry. To explore this possibility, we set
13 out experiments to examine whether the percentage of spines invaded by dynamic microtubules
14 correlated with spine resistance to $\text{oA}\beta$ in neurons ectopically expressing tubulin tyrosine ligase
15 (Figure 6E-G). We found that expression of tubulin tyrosine ligase averted the $\text{oA}\beta$ -induced drop
16 in spine invasions by dynamic microtubules measured at 30 minutes (Figure 6F) as well as $\text{oA}\beta$ -
17 promoted spine loss, which became detectable only 2.5 hours later (Figure 6G). To assess
18 whether this drop in spine entries at 30 minutes could be related to the loss of tubulin tyrosine
19 ligase and tyrosinated tubulin, we evaluated microtubule entries into spines when tubulin
20 tyrosine ligase levels start to decrease. In hippocampal rat neurons, after 4 days of infection with
21 shRNA against tubulin tyrosine ligase, a time point at which tubulin tyrosine ligase levels begin
22 to drop but before spine density starts to decline, microtubule entries into spines significantly
23 decreased (Supplementary Fig. 7A-B). Accordingly, in the TTL \pm mouse neuronal cultures,
24 there was also a significant decrease in spine entries, as compared to the WT (Supplementary
25 Fig. 7C).

26 Together, our results indicate that entry of dynamic tyrosinated microtubules into spines may
27 underlie enhanced resistance of dendritic spines to synaptic injury and that restoring tubulin
28 tyrosine ligase expression can protect dendritic spines from $\text{oA}\beta$ toxicity as illustrated in Figure
29 7.

30

1 Discussion

2 In this study, we identify a role for the retyrosination of α -tubulin by tubulin tyrosine ligase
3 activity in the maintenance of synaptic function and Alzheimer disease-related synaptic
4 dysfunction.

5 Our biochemical and immuno-histological analysis of TTL^{+/-} mouse hippocampi confirmed that
6 hemizygous suppression of tubulin tyrosine ligase leads to around 40% reduction of tyrosinated
7 tubulin, and that this reduction is compatible with viability and normal life span. This result
8 suggests that tubulin tyrosine ligase levels are rate-limiting for the maintenance of physiological
9 amounts of tyrosinated tubulin *in vivo*.

10 We found that the behavioral performance of TTL^{+/-} mice at 3 months revealed impairments in
11 spontaneous alternation test and novel object recognition but no defect in spatial learning
12 assessed by Morris Water Maze, the standard test for evaluating hippocampal-dependent
13 memory in rodents. This behavioral profile was consistent with no alteration in hippocampal
14 basal transmission and CA3/CA1 LTP at this early age, which was instead characterized by
15 deficits in spatial working and intermediate-term recognition memory most likely caused by
16 cortical circuitry dysfunction. In agreement with synaptic cortical damage at this age, we
17 observed loss of dendritic spines in serial sections obtained from cortical layer V of 3-month-old
18 TTL^{+/-} mice. At 9 months, however, TTL^{+/-} mice had a clear reduction in their basal hippocampal
19 transmission, a defect consistent with decreased spine density observed in cultured hippocampal
20 neurons from TTL^{+/-} embryos or transiently silenced of tubulin tyrosine ligase expression. In
21 addition, a striking decline in the LTP of synaptic strength at the Schaffer collateral synapses was
22 observable in 9-month-old TTL^{+/-} mice, demonstrating that tubulin tyrosine ligase deficiency
23 exacerbates synaptic plasticity defects with aging.

24 Our *in vitro* analyses strongly suggest that these alterations may be related to defects in synaptic
25 microtubule dynamics. In support of this model, we found that loss of tubulin tyrosine ligase
26 significantly reduced the number of microtubule entries into dendritic spines and led to a
27 significant loss of synapses. In addition, we found that entry of dynamic microtubules into spines
28 correlated with resistance to α A β -induced spine pruning. Strikingly, expression of tubulin
29 tyrosine ligase in α A β -treated neurons prevented both transient loss of microtubule entry into
30 spines and spine pruning, indicating that restoring dynamic microtubule invasions into spines is

1 the mechanism by which tubulin tyrosine ligase prevents α A β -induced loss of synapses.
2 Matching our observed decline in tubulin tyrosine ligase and tyrosinated tubulin after 30 minutes
3 and 3 hours of 250 nM α A β , previous research has shown that in primary hippocampal neurons
4 microtubules present in the dendritic shaft become less dynamic after 30 minutes of α A β
5 exposure and that detyrosinated tubulin levels increase by 3 hours.⁷² The fine-tuning of the
6 tyrosination-detyrosination tubulin cycle as a function of small, local cues may be important in
7 the vicinity of synapses which are particularly dependent on entry of dynamic tyrosinated
8 microtubules.^{10, 11} Live imaging of spines invaded by microtubules during incubation with α A β
9 showed that the minority of spines that were invaded by microtubules during the recording
10 period had a greater resistance to pruning than non-invaded spines. Given the pleiotropic effects
11 that the tyrosination-detyrosination tubulin cycle plays in the regulation of neuronal transport,^{45,}
12 ⁹⁴⁻⁹⁶ local re-tyrosination of tubulin by tubulin tyrosine ligase might be critical for the recruitment
13 or removal of spine modulating cargos specifically trafficked along tyrosinated microtubules. We
14 have observed a population of spines that are not invaded by microtubules and yet persist. There
15 may be at least two plausible explanations for this: 1) the resistant spine lacking microtubule
16 invasion might have been invaded prior to movie acquisition; 2) only a small fraction of spines is
17 invaded at any given time, suggesting that not all spines have the same chance to be targeted by
18 microtubules and/or are dependent on microtubules to avoid pruning. If not all spines are equally
19 targeted, this would also explain why certain spines may be more resistant or particularly
20 vulnerable to pruning.

21 Altogether, the electrophysiological, spine density and behavioral profile of TTL^{+/-} mice shows
22 that tubulin tyrosine ligase is required for synaptic maintenance and plasticity, and that tubulin
23 tyrosine ligase deficiency increases synaptic vulnerability. These findings are relevant to the
24 onset of synaptic dysfunction in neurodegenerative disease, as we find that tubulin tyrosine
25 ligase is down-regulated in Alzheimer's disease brain, human Alzheimer's disease neurons, and
26 primary neurons exposed to α A β . Biochemical analysis of *postmortem* brain samples from
27 clinically graded Alzheimer's disease patients indicated a robust loss of tubulin tyrosine ligase
28 and a gain in detyrosinated and Δ 2 tubulin compared to samples from non-affected individuals in
29 the same age range. The correlation between disease conditions and non-tyrosinated tubulin
30 accumulation was confirmed at the single neuron level by imaging analysis of Alzheimer's
31 disease hippocampal sections. Deficits were narrowed to an early phase of the disease, a stage at

1 which neuron morphology appears normal with deficiencies mainly affecting the synaptic
2 compartments. Our data also point out that in Alzheimer's disease the accumulation of non-
3 tyrosinated forms of tubulin affects the whole brain, suggesting that selected circuits that go
4 awry in Alzheimer's disease may be more vulnerable than others to loss of tubulin re-
5 tyrosination.

6 The finding that the knock-in of the Alzheimer's disease-linked London mutation in APP in *in*
7 *vitro* differentiated human neurons also resulted in a drop in tubulin tyrosine ligase compared to
8 isogenic controls strongly supports a causal relationship between tubulin tyrosine ligase loss and
9 familial Alzheimer's disease. Because the London mutation leads to an increase in the
10 amyloidogenic processing of APP and overproduction of toxic Amyloid β species,⁹² the finding
11 suggests that tubulin tyrosine ligase down-regulation could be initiated by either defective APP
12 processing and/or accumulation of $\alpha\text{A}\beta$. Indeed, chronic incubation of cultured mouse neurons
13 with synthetic $\alpha\text{A}\beta$ elicited a significant decline in tubulin tyrosine ligase levels, although the
14 underlying mechanisms are yet to be defined. The altered synaptic phenotype of $\text{TTL}^{+/-}$ mice
15 suggests that down-regulation of tubulin tyrosine ligase might in turn aggravate $\alpha\text{A}\beta$
16 synaptotoxicity by reducing microtubule dynamics, and thus cause further loss of synapses. This
17 notion would be consistent with the protection against dendritic spine retraction that we observed
18 in neurons in which tubulin tyrosine ligase was ectopically expressed.

19 Altogether, our results point to a modulatory role of the tyrosination/detyrosination tubulin cycle in
20 synaptic plasticity and indicate that loss of tubulin tyrosine ligase and tubulin re-tyrosination are
21 features of Alzheimer's disease and might be one of the mechanisms playing a pathogenic role at early
22 stages of neurodegeneration. The results also indicate that in the early stages of Alzheimer's disease,
23 the microtubule network appears to be less dynamic than in normal conditions, with critical loss of
24 dynamic microtubules. They also suggest that the decrease in dynamic microtubules, rather than a
25 global microtubule destabilization, initiates Alzheimer's disease pathology. Our pathogenesis model
26 does not reject loss of microtubule integrity as a major pathological feature of advanced Alzheimer's
27 disease, but rather proposes that amyloidogenic APP processing may affect synaptic function by
28 reducing the population of dynamic microtubules entering into synapses at an early stage of the disease.
29 While the molecular factors associated with the resistance of dynamic microtubules-invaded spines
30 remain to be identified, our results suggest that tubulin tyrosine ligase activators may be beneficial to
31 restore circuit integrity in sporadic and familial Alzheimer's disease. In addition, the VASH1/2-SVBP
32 carboxypeptidases have been recently identified as a tubulin detyrosinating complexes^{20, 21} suggesting

1 that also drugs able to modulate tubulin carboxypeptidase activity may offer a valuable new approach
2 for therapeutic intervention in Alzheimer's disease.

3 **Acknowledgements**

4 We thank F. Vossier and L. Macedo for technical support; S. Andrieu, L. Romian, F. Mehr, F. Rimet, and S
5 Bama-Toupet for animal care; Ju. Brocard for help in lentivirus preparation and E. Tein for conducting
6 hiPSC neuronal differentiations. We are grateful to J. Crary (Icahn School of Medicine at Mount Sinai)
7 and the Pathology Dept at CUIMC for kindly providing Alzheimer's disease and age matched control
8 brain slices from *post-mortem* tissue. We thank M. Gagliardini and S. Jules for helping with the analysis
9 of *post-mortem* specimens and S. Pierre-Ferrer for the characterization of lentiviral shTTL vectors in
10 primary neuronal cultures.

11 **Funding**

12 Part of the work was performed at Grenoble Institut Neuroscience Photonic Imaging Center (part of the
13 IBISA-accredited ISdV core facility) and in CEA-IRIG animal facility (GRAL, ANR-17-EURE-0003). This work
14 was supported by INSERM; CEA; CNRS; University Grenoble Alpes; France Alzheimer (CAPAlz-AAP SM
15 2018) and ANR (SPEED-Y, ANR-20-CE16-0021) grants to MJM; NIH/NIA RO3 AG060025, NIH/NIA RO1
16 AG050658 and NIH/NINDS R21 NS120076-01 grants to FB; RO3 AG060025 (Co-I), the Henry and Marilyn
17 Taub Foundation, and the Thompson Foundation (TAME-AD) grants to AS. JP fellowship was from the
18 Italian Academy at Columbia University and the Alzheimer's Association Grant AARF-20-685875; MBR
19 postdoctoral fellowship from Ramón Areces Foundation and salaries of JMH, CC and GF from a
20 collaborative program between Servier laboratories and AA's team.

21 **Contributions**

22 LP, XQ, JP, MJM, FB and AA conceived and designed the study. CB, GF, MEP, XQ, AK and JP performed
23 molecular biology experiments and TTL lentivirus preparations. AA and MJM supervised TTL mice
24 production, BDC and PD supervised behavioral tests and mouse brains biochemical studies. FL, FP and
25 AB performed electrophysiological experiments. SGF performed and analyzed in vivo dendritic spine
26 density. LP and JMH performed experiments to analyze spine density in mouse hippocampal neurons.
27 FB, MEP and JP designed and performed the analysis of spine density in rat hippocampal neurons. JMS

1 and CC performed biochemical experiments with AD patient samples, JB and YG performed the
2 associated statistical analysis. FB and XQ designed and performed in situ analysis of patient data. FB, JP,
3 XQ and AK designed and performed analysis of microtubule entry into dendritic spines. FB, AK, JP, MBR,
4 and AS designed and performed experiments in human cortical neurons. FB and JP designed and
5 performed biochemical studies in rat neurons. LP, JP, YG, MJM, FB and AA wrote the manuscript, with
6 contributions from all co-authors.

7 **Competing interests**

8 The authors report no competing interests.

9 **Supplementary material**

10 Supplementary material is available at *Brain* online.

11

12

ACCEPTED MANUSCRIPT

1 **References**

- 2 1. Parato J, Bartolini F. The microtubule cytoskeleton at the synapse. *Neurosci Lett*. Mar 26
3 2021;753:135850. doi:10.1016/j.neulet.2021.135850
- 4 2. Waites C, Qu X, Bartolini F. The synaptic life of microtubules. *Curr Opin Neurobiol*. Apr 16
5 2021;69:113-123. doi:10.1016/j.conb.2021.03.004
- 6 3. Qu X, Kumar A, Blockus H, Waites C, Bartolini F. Activity-Dependent Nucleation of Dynamic
7 Microtubules at Presynaptic Boutons Controls Neurotransmission. *Curr Biol*. Dec 16 2019;29(24):4231-
8 4240 e5. doi:10.1016/j.cub.2019.10.049
- 9 4. Guedes-Dias P, Nirschl JJ, Abreu N, et al. Kinesin-3 Responds to Local Microtubule Dynamics to
10 Target Synaptic Cargo Delivery to the Presynapse. *Curr Biol*. Jan 21 2019;29(2):268-282 e8.
11 doi:10.1016/j.cub.2018.11.065
- 12 5. Guillaud L, Dimitrov D, Takahashi T. Presynaptic morphology and vesicular composition
13 determine vesicle dynamics in mouse central synapses. *eLife*. Apr 22 2017;6doi:10.7554/eLife.24845
- 14 6. Piriya Ananda Babu L, Wang HY, Eguchi K, Guillaud L, Takahashi T. Microtubule and Actin
15 Differentially Regulate Synaptic Vesicle Cycling to Maintain High-Frequency Neurotransmission. *The
16 Journal of neuroscience : the official journal of the Society for Neuroscience*. Jan 2 2020;40(1):131-142.
17 doi:10.1523/JNEUROSCI.1571-19.2019
- 18 7. Dent EW. Dynamic microtubules at the synapse. *Curr Opin Neurobiol*. Aug 2020;63:9-14.
19 doi:10.1016/j.conb.2020.01.003
- 20 8. McVicker DP, Awe AM, Richters KE, et al. Transport of a kinesin-cargo pair along microtubules
21 into dendritic spines undergoing synaptic plasticity. *Nature communications*. Sep 23 2016;7:12741.
22 doi:10.1038/ncomms12741
- 23 9. Mitsuyama F, Niimi G, Kato K, et al. Redistribution of microtubules in dendrites of hippocampal
24 CA1 neurons after tetanic stimulation during long-term potentiation. *Ital J Anat Embryol*. Jan-Mar
25 2008;113(1):17-27.
- 26 10. Hu X, Viesselmann C, Nam S, Merriam E, Dent EW. Activity-dependent dynamic microtubule
27 invasion of dendritic spines. *The Journal of neuroscience : the official journal of the Society for
28 Neuroscience*. Dec 3 2008;28(49):13094-105. doi:10.1523/JNEUROSCI.3074-08.2008
- 29 11. Jaworski J, Kapitein LC, Gouveia SM, et al. Dynamic microtubules regulate dendritic spine
30 morphology and synaptic plasticity. *Neuron*. Jan 15 2009;61(1):85-100.
31 doi:10.1016/j.neuron.2008.11.013
- 32 12. Schatzle P, Esteves da Silva M, Tas RP, et al. Activity-Dependent Actin Remodeling at the Base
33 of Dendritic Spines Promotes Microtubule Entry. *Curr Biol*. Jul 9 2018;28(13):2081-2093 e6.
34 doi:10.1016/j.cub.2018.05.004
- 35 13. Kapitein LC, Yau KW, Gouveia SM, et al. NMDA receptor activation suppresses microtubule
36 growth and spine entry. *The Journal of neuroscience : the official journal of the Society for Neuroscience*.
37 Jun 1 2011;31(22):8194-209. doi:10.1523/JNEUROSCI.6215-10.2011
- 38 14. Merriam EB, Lumbard DC, Viesselmann C, et al. Dynamic microtubules promote synaptic
39 NMDA receptor-dependent spine enlargement. *PloS one*. 2011;6(11):e27688.
40 doi:10.1371/journal.pone.0027688
- 41 15. Merriam EB, Millette M, Lumbard DC, et al. Synaptic regulation of microtubule dynamics in
42 dendritic spines by calcium, F-actin, and drebrin. *The Journal of neuroscience : the official journal of the
43 Society for Neuroscience*. Oct 16 2013;33(42):16471-82. doi:10.1523/JNEUROSCI.0661-13.2013
- 44 16. Shumyatsky GP, Malleret G, Shin RM, et al. stathmin, a gene enriched in the amygdala, controls
45 both learned and innate fear. *Cell*. Nov 18 2005;123(4):697-709. doi:10.1016/j.cell.2005.08.038
- 46 17. Uchida S, Martel G, Pavlowsky A, et al. Learning-induced and stathmin-dependent changes in
47 microtubule stability are critical for memory and disrupted in ageing. *Nature communications*. Jul 10
48 2014;5:4389. doi:10.1038/ncomms5389

- 1 18. Gadadhar S, Bodakuntla S, Natarajan K, Janke C. The tubulin code at a glance. *J Cell Sci.* Apr 15
2 2017;130(8):1347-1353. doi:10.1242/jcs.199471
- 3 19. Moutin MJ, Bosc C, Peris L, Andrieux A. Tubulin post-translational modifications control
4 neuronal development and functions. *Developmental neurobiology.* Jul 22 2020;doi:10.1002/dneu.22774
- 5 20. Aillaud C, Bosc C, Peris L, et al. Vasohibins/SVBP are tubulin carboxypeptidases (TCPs) that
6 regulate neuron differentiation. *Science.* Dec 15 2017;358(6369):1448-1453.
7 doi:10.1126/science.aao4165
- 8 21. Nieuwenhuis J, Adamopoulos A, Bleijerveld OB, et al. Vasohibins encode tubulin detyrosinating
9 activity. *Science.* Dec 15 2017;358(6369):1453-1456. doi:10.1126/science.aao5676
- 10 22. Wang N, Bosc C, Ryul Choi S, et al. Structural basis of tubulin detyrosination by the vasohibin-
11 SVBP enzyme complex. *Nat Struct Mol Biol.* Jul 2019;26(7):571-582. doi:10.1038/s41594-019-0241-y
- 12 23. Barra HS, Rodriguez JA, Arce CA, Caputto R. A soluble preparation from rat brain that
13 incorporates into its own proteins (14 C)arginine by a ribonuclease-sensitive system and (14 C)tyrosine
14 by a ribonuclease-insensitive system. *J Neurochem.* Jan 1973;20(1):97-108. doi:10.1111/j.1471-
15 4159.1973.tb12108.x
- 16 24. Baas PW, Black MM. Individual microtubules in the axon consist of domains that differ in both
17 composition and stability. *J Cell Biol.* 1990-08-01 1990;111(2):495-509. doi:10.1083/jcb.111.2.495
- 18 25. Bre MH, Kreis TE, Karsenti E. Control of microtubule nucleation and stability in Madin-Darby
19 canine kidney cells: the occurrence of noncentrosomal, stable detyrosinated microtubules. *J Cell Biol.* Sep
20 1987;105(3):1283-96. doi:10.1083/jcb.105.3.1283
- 21 26. Kreis TE. Microtubules containing detyrosinated tubulin are less dynamic. *EMBO J.* Sep
22 1987;6(9):2597-606.
- 23 27. Prota AE, Magiera MM, Kuijpers M, et al. Structural basis of tubulin tyrosination by tubulin
24 tyrosine ligase. *J Cell Biol.* Feb 4 2013;200(3):259-70. doi:10.1083/jcb.201211017
- 25 28. Paturle-Lafanechere L, Edde B, Denoulet P, et al. Characterization of a major brain tubulin
26 variant which cannot be tyrosinated. *Biochemistry.* Oct 29 1991;30(43):10523-8.
27 doi:10.1021/bi00107a022
- 28 29. Rogowski K, van Dijk J, Magiera MM, et al. A family of protein-deglutamylating enzymes
29 associated with neurodegeneration. *Cell.* Nov 12 2010;143(4):564-78. doi:10.1016/j.cell.2010.10.014
- 30 30. Tort O, Tanco S, Rocha C, et al. The cytosolic carboxypeptidases CCP2 and CCP3 catalyze
31 posttranslational removal of acidic amino acids. *Mol Biol Cell.* Oct 1 2014;25(19):3017-27.
32 doi:10.1091/mbc.E14-06-1072
- 33 31. Aillaud C, Bosc C, Saoudi Y, et al. Evidence for new C-terminally truncated variants of alpha-
34 and beta-tubulins. *Mol Biol Cell.* Feb 15 2016;27(4):640-53. doi:10.1091/mbc.E15-03-0137
- 35 32. Paturle-Lafanechere L, Manier M, Trigault N, Pirollet F, Mazarguil H, Job D. Accumulation of
36 delta 2-tubulin, a major tubulin variant that cannot be tyrosinated, in neuronal tissues and in stable
37 microtubule assemblies. *J Cell Sci.* Jun 1994;107 (Pt 6):1529-43.
- 38 33. Peris L, Thery M, Faure J, et al. Tubulin tyrosination is a major factor affecting the recruitment of
39 CAP-Gly proteins at microtubule plus ends. *J Cell Biol.* Sep 11 2006;174(6):839-49.
40 doi:10.1083/jcb.200512058
- 41 34. Pagnamenta AT, Heemeryck P, Martin HC, et al. Defective tubulin detyrosination causes
42 structural brain abnormalities with cognitive deficiency in humans and mice. *Hum Mol Genet.* Oct 15
43 2019;28(20):3391-3405. doi:10.1093/hmg/ddz186
- 44 35. Pero ME, Meregalli C, Qu X, et al. Pathogenic role of delta 2 tubulin in bortezomib-induced
45 peripheral neuropathy. *Proc Natl Acad Sci U S A.* Jan 26 2021;118(4)doi:10.1073/pnas.2012685118
- 46 36. Webster DR, Gundersen GG, Bulinski JC, Borisy GG. Differential turnover of tyrosinated and
47 detyrosinated microtubules. *Proc Natl Acad Sci U S A.* Dec 1987;84(24):9040-4.
48 doi:10.1073/pnas.84.24.9040
- 49 37. Webster DR, Gundersen GG, Bulinski JC, Borisy GG. Assembly and turnover of detyrosinated
50 tubulin in vivo. *J Cell Biol.* Jul 1987;105(1):265-76. doi:10.1083/jcb.105.1.265

- 1 38. Khawaja S, Gundersen GG, Bulinski JC. Enhanced stability of microtubules enriched in
2 detyrosinated tubulin is not a direct function of detyrosination level. *J Cell Biol.* Jan 1988;106(1):141-9.
3 doi:10.1083/jcb.106.1.141
- 4 39. Gundersen GG, Bulinski JC. Selective stabilization of microtubules oriented toward the direction
5 of cell migration. *Proc Natl Acad Sci U S A.* Aug 1988;85(16):5946-50. doi:10.1073/pnas.85.16.5946
- 6 40. Peris L, Wagenbach M, Lafanechere L, et al. Motor-dependent microtubule disassembly driven
7 by tubulin tyrosination. *J Cell Biol.* Jun 29 2009;185(7):1159-66. doi:10.1083/jcb.200902142
- 8 41. Dunn S, Morrison EE, Liverpool TB, et al. Differential trafficking of Kif5c on tyrosinated and
9 detyrosinated microtubules in live cells. *J Cell Sci.* Apr 1 2008;121(Pt 7):1085-95.
10 doi:10.1242/jcs.026492
- 11 42. Hammond JW, Huang CF, Kaech S, Jacobson C, Banker G, Verhey KJ. Posttranslational
12 modifications of tubulin and the polarized transport of kinesin-1 in neurons. *Mol Biol Cell.* Feb 15
13 2010;21(4):572-83. doi:10.1091/mbc.E09-01-0044
- 14 43. Konishi Y, Setou M. Tubulin tyrosination navigates the kinesin-1 motor domain to axons. *Nat*
15 *Neurosci.* May 2009;12(5):559-67. doi:10.1038/nn.2314
- 16 44. Guardia CM, Farias GG, Jia R, Pu J, Bonifacino JS. BORC Functions Upstream of Kinesins 1
17 and 3 to Coordinate Regional Movement of Lysosomes along Different Microtubule Tracks. *Cell reports.*
18 Nov 15 2016;17(8):1950-1961. doi:10.1016/j.celrep.2016.10.062
- 19 45. Tas RP, Chazeau A, Cloin BMC, Lambers MLA, Hoogenraad CC, Kapitein LC. Differentiation
20 between Oppositely Oriented Microtubules Controls Polarized Neuronal Transport. *Neuron.* Dec 20
21 2017;96(6):1264-1271 e5. doi:10.1016/j.neuron.2017.11.018
- 22 46. Kaul N, Soppina V, Verhey KJ. Effects of alpha-tubulin K40 acetylation and detyrosination on
23 kinesin-1 motility in a purified system. *Biophys J.* Jun 17 2014;106(12):2636-43.
24 doi:10.1016/j.bpj.2014.05.008
- 25 47. Kreitzer G, Liao G, Gundersen GG. Detyrosination of tubulin regulates the interaction of
26 intermediate filaments with microtubules in vivo via a kinesin-dependent mechanism. *Mol Biol Cell.* Apr
27 1999;10(4):1105-18. doi:10.1091/mbc.10.4.1105
- 28 48. Liao G, Kreitzer G, Cook TA, Gundersen GG. A signal transduction pathway involved in
29 microtubule-mediated cell polarization. *FASEB journal : official publication of the Federation of*
30 *American Societies for Experimental Biology.* Dec 1999;13 Suppl 2:S257-60.
31 doi:10.1096/fasebj.13.9002.s257
- 32 49. Sirajuddin M, Rice LM, Vale RD. Regulation of microtubule motors by tubulin isotypes and
33 post-translational modifications. *Nat Cell Biol.* Apr 2014;16(4):335-44. doi:10.1038/ncb2920
- 34 50. Cai D, McEwen DP, Martens JR, Meyhofer E, Verhey KJ. Single molecule imaging reveals
35 differences in microtubule track selection between Kinesin motors. *PLoS Biol.* Oct 2009;7(10):e1000216.
36 doi:10.1371/journal.pbio.1000216
- 37 51. Nirschl JJ, Magiera MM, Lazarus JE, Janke C, Holzbaur EL. alpha-Tubulin Tyrosination and
38 CLIP-170 Phosphorylation Regulate the Initiation of Dynein-Driven Transport in Neurons. *Cell reports.*
39 Mar 22 2016;14(11):2637-52. doi:10.1016/j.celrep.2016.02.046
- 40 52. Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP. Linking axonal
41 degeneration to microtubule remodeling by Spastin-mediated microtubule severing. *J Cell Biol.* Feb 14
42 2005;168(4):599-606. doi:10.1083/jcb.200409058
- 43 53. Roll-Mecak A, Vale RD. Structural basis of microtubule severing by the hereditary spastic
44 paraplegia protein spastin. *Nature.* Jan 17 2008;451(7176):363-7. doi:10.1038/nature06482
- 45 54. Schwarz TL. Mitochondrial trafficking in neurons. *Cold Spring Harbor perspectives in biology.*
46 Jun 1 2013;5(6)doi:10.1101/cshperspect.a011304
- 47 55. Setou M, Seog DH, Tanaka Y, et al. Glutamate-receptor-interacting protein GRIP1 directly steers
48 kinesin to dendrites. *Nature.* May 2 2002;417(6884):83-7. doi:10.1038/nature743
- 49 56. Hoerndli FJ, Maxfield DA, Brockie PJ, et al. Kinesin-1 regulates synaptic strength by mediating
50 the delivery, removal, and redistribution of AMPA receptors. *Neuron.* Dec 18 2013;80(6):1421-37.
51 doi:10.1016/j.neuron.2013.10.050

- 1 57. Nakajima K, Yin X, Takei Y, Seog DH, Homma N, Hirokawa N. Molecular motor KIF5A is
2 essential for GABA(A) receptor transport, and KIF5A deletion causes epilepsy. *Neuron*. Dec 6
3 2012;76(5):945-61. doi:10.1016/j.neuron.2012.10.012
- 4 58. Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, et al. Delivery of GABAARs to synapses is
5 mediated by HAP1-KIF5 and disrupted by mutant huntingtin. *Neuron*. Jan 14 2010;65(1):53-65.
6 doi:10.1016/j.neuron.2009.12.007
- 7 59. Yin X, Feng X, Takei Y, Hirokawa N. Regulation of NMDA receptor transport: a KIF17-cargo
8 binding/releasing underlies synaptic plasticity and memory in vivo. *The Journal of neuroscience : the*
9 *official journal of the Society for Neuroscience*. Apr 18 2012;32(16):5486-99.
10 doi:10.1523/JNEUROSCI.0718-12.2012
- 11 60. Erck C, Peris L, Andrieux A, et al. A vital role of tubulin-tyrosine-ligase for neuronal
12 organization. *Proc Natl Acad Sci U S A*. May 31 2005;102(22):7853-8. doi:10.1073/pnas.0409626102
- 13 61. Iqbal Z, Tawamie H, Ba W, et al. Loss of function of SVBP leads to autosomal recessive
14 intellectual disability, microcephaly, ataxia, and hypotonia. *Genetics in medicine : official journal of the*
15 *American College of Medical Genetics*. Aug 2019;21(8):1790-1796. doi:10.1038/s41436-018-0415-8
- 16 62. Marcos S, Moreau J, Backer S, Job D, Andrieux A, Bloch-Gallego E. Tubulin tyrosination is
17 required for the proper organization and pathfinding of the growth cone. *PloS one*. 2009;4(4):e5405.
18 doi:10.1371/journal.pone.0005405
- 19 63. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. *Nature*
20 *reviews Neuroscience*. Feb 2011;12(2):65-72. doi:10.1038/nrn2967
- 21 64. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's
22 disease and mild cognitive impairment. *Neurobiol Aging*. Oct 2006;27(10):1372-84.
23 doi:10.1016/j.neurobiolaging.2005.09.012
- 24 65. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's
25 disease: synapse loss is the major correlate of cognitive impairment. *Ann Neurol*. Oct 1991;30(4):572-80.
26 doi:10.1002/ana.410300410
- 27 66. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet*. Jul 29 2006;368(9533):387-
28 403. doi:10.1016/S0140-6736(06)69113-7
- 29 67. Tanzi RE, Hyman BT. Alzheimer's mutation. *Nature*. Apr 18 1991;350(6319):564.
30 doi:10.1038/350564a0
- 31 68. Muratore CR, Rice HC, Srikanth P, et al. The familial Alzheimer's disease APPV717I mutation
32 alters APP processing and Tau expression in iPSC-derived neurons. *Hum Mol Genet*. Jul 1
33 2014;23(13):3523-36. doi:10.1093/hmg/ddu064
- 34 69. Nirmalraj PN, List J, Battacharya S, et al. Complete aggregation pathway of amyloid beta (1-40)
35 and (1-42) resolved on an atomically clean interface. *Science advances*. Apr 2020;6(15):eaaz6014.
36 doi:10.1126/sciadv.aaz6014
- 37 70. Mann DM, Iwatsubo T, Ihara Y, et al. Predominant deposition of amyloid-beta 42(43) in plaques
38 in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the
39 amyloid precursor protein gene. *Am J Pathol*. Apr 1996;148(4):1257-66.
- 40 71. Vu HT, Akatsu H, Hashizume Y, Setou M, Ikegami K. Increase in alpha-tubulin modifications in
41 the neuronal processes of hippocampal neurons in both kainic acid-induced epileptic seizure and
42 Alzheimer's disease. *Scientific reports*. Jan 9 2017;7:40205. doi:10.1038/srep40205
- 43 72. Qu X, Yuan FN, Corona C, et al. Stabilization of dynamic microtubules by mDial drives Tau-
44 dependent Abeta1-42 synaptotoxicity. *J Cell Biol*. Oct 2 2017;216(10):3161-3178.
45 doi:10.1083/jcb.201701045
- 46 73. Muhia M, Thies E, Labonte D, et al. The Kinesin KIF21B Regulates Microtubule Dynamics and
47 Is Essential for Neuronal Morphology, Synapse Function, and Learning and Memory. *Cell reports*. May 3
48 2016;15(5):968-977. doi:10.1016/j.celrep.2016.03.086
- 49 74. Feng G, Mellor RH, Bernstein M, et al. Imaging neuronal subsets in transgenic mice expressing
50 multiple spectral variants of GFP. *Neuron*. Oct 2000;28(1):41-51. doi:10.1016/s0896-6273(00)00084-2

- 1 75. Peris L, Bisbal M, Martinez-Hernandez J, et al. A key function for microtubule-associated-protein
2 6 in activity-dependent stabilisation of actin filaments in dendritic spines. *Nature communications*. Sep 17
3 2018;9(1):3775. doi:10.1038/s41467-018-05869-z
- 4 76. Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. Automated three-dimensional
5 detection and shape classification of dendritic spines from fluorescence microscopy images. *PLoS one*.
6 Apr 23 2008;3(4):e1997. doi:10.1371/journal.pone.0001997
- 7 77. Stepanova T, Smal I, van Haren J, et al. History-dependent catastrophes regulate axonal
8 microtubule behavior. *Curr Biol*. Jun 8 2010;20(11):1023-8. doi:10.1016/j.cub.2010.04.024
- 9 78. Wehland J, Weber K. Tubulin-tyrosine ligase has a binding site on beta-tubulin: a two-domain
10 structure of the enzyme. *J Cell Biol*. Apr 1987;104(4):1059-67. doi:10.1083/jcb.104.4.1059
- 11 79. Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains
12 for research: the Columbia University methods. *Acta neuropathologica*. May 2008;115(5):509-32.
13 doi:10.1007/s00401-007-0311-9
- 14 80. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from
15 human somatic cells. *Science*. Dec 21 2007;318(5858):1917-20. doi:10.1126/science.1151526
- 16 81. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and
17 transgene sequences. *Science*. May 8 2009;324(5928):797-801. doi:10.1126/science.1172482
- 18 82. Hu K, Yu J, Suknutha K, et al. Efficient generation of transgene-free induced pluripotent stem
19 cells from normal and neoplastic bone marrow and cord blood mononuclear cells. *Blood*. Apr 7
20 2011;117(14):e109-19. doi:10.1182/blood-2010-07-298331
- 21 83. Sun J, Carlson-Stevermer J, Das U, et al. CRISPR/Cas9 editing of APP C-terminus attenuates
22 beta-cleavage and promotes alpha-cleavage. *Nature communications*. Jan 3 2019;10(1):53.
23 doi:10.1038/s41467-018-07971-8
- 24 84. Topol A, Tran NN, Brennand KJ. A guide to generating and using hiPSC derived NPCs for the
25 study of neurological diseases. *Journal of visualized experiments : JoVE*. Feb 21 2015;(96):e52495.
26 doi:10.3791/52495
- 27 85. Cheng C, Fass DM, Folz-Donahue K, MacDonald ME, Haggarty SJ. Highly Expandable Human
28 iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease
29 Modeling and High-Throughput Screening. *Curr Protoc Hum Genet*. Jan 11 2017;92:21 8 1-21 8 21.
30 doi:10.1002/cphg.33
- 31 86. Miedel CJ, Patton JM, Miedel AN, Miedel ES, Levenson JM. Assessment of Spontaneous
32 Alternation, Novel Object Recognition and Limb Claspings in Transgenic Mouse Models of Amyloid-beta
33 and Tau Neuropathology. *Journal of visualized experiments : JoVE*. May 28
34 2017;(123)doi:10.3791/55523
- 35 87. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model
36 improves memory function. *Science*. Jul 15 2005;309(5733):476-81. doi:10.1126/science.1113694
- 37 88. Hsiao K, Chapman P, Nilsson S, et al. Correlative memory deficits, Aβ elevation, and amyloid
38 plaques in transgenic mice. *Science*. Oct 4 1996;274(5284):99-102. doi:10.1126/science.274.5284.99
- 39 89. Sasaguri H, Nilsson P, Hashimoto S, et al. APP mouse models for Alzheimer's disease preclinical
40 studies. *EMBO J*. Sep 1 2017;36(17):2473-2487. doi:10.15252/embj.201797397
- 41 90. Harris KM, Weinberg RJ. Ultrastructure of synapses in the mammalian brain. *Cold Spring
42 Harbor perspectives in biology*. May 1 2012;4(5)doi:10.1101/cshperspect.a005587
- 43 91. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol
44 Aging*. May-Jun 1995;16(3):271-8; discussion 278-84. doi:10.1016/0197-4580(95)00021-6
- 45 92. Pahrudin Arrozi A, Shukri SNS, Wan Ngah WZ, Mohd Yusof YA, Ahmad Damanhuri MH,
46 Makpol S. Evaluation of the Expression of Amyloid Precursor Protein and the Ratio of Secreted Amyloid
47 Beta 42 to Amyloid Beta 40 in SH-SY5Y Cells Stably Transfected with Wild-Type, Single-Mutant and
48 Double-Mutant Forms of the APP Gene for the Study of Alzheimer's Disease Pathology. *Appl Biochem
49 Biotechnol*. Nov 2017;183(3):853-866. doi:10.1007/s12010-017-2468-6

- 1 93. Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P. Amyloid beta
2 oligomers (AbetaOs) in Alzheimer's disease. *J Neural Transm (Vienna)*. Feb 2018;125(2):177-191.
3 doi:10.1007/s00702-017-1820-x
- 4 94. Maeder CI, Shen K, Hoogenraad CC. Axon and dendritic trafficking. *Curr Opin Neurobiol*. Aug
5 2014;27:165-70. doi:10.1016/j.conb.2014.03.015
- 6 95. van den Berg R, Hoogenraad CC. Molecular motors in cargo trafficking and synapse assembly.
7 *Adv Exp Med Biol*. 2012;970:173-96. doi:10.1007/978-3-7091-0932-8_8
- 8 96. Kapitein LC, Hoogenraad CC. Which way to go? Cytoskeletal organization and polarized
9 transport in neurons. Research Support, Non-U.S. Gov't
10 Review. *Molecular and cellular neurosciences*. Jan 2011;46(1):9-20. doi:10.1016/j.mcn.2010.08.015

11
12

1 **Figures legends**

2 **Figure 1. Tubulin tyrosine ligase reduction induces early memory defects and age-dependent**
 3 **alteration of synaptic plasticity. (A)** Schematic representation of α -tubulin tyrosination/detyrosination
 4 cycle. TTL (tubulin tyrosine ligase), SVBP (small vasohibin-binding protein), VASH-1/2 (vasohibin-1 and -
 5 2), CCPs (cytosolic carboxypeptidases). **(B-C)** Relative amount of TTL (normalized with GAPDH) and
 6 tyrosinated/detyrosinated tubulin ratio, in protein extracts from hippocampi of 3-month-old WT and
 7 Tubulin Tyrosine Ligase heterozygous (TTL^{+/-}) mice. Graphs represents mean \pm SEM. Mann-Whitney test,
 8 ** $p < 0.01$, **** $p < 0.0001$. $n = 10$ independent experiments for each genotype. **(D)** Spontaneous
 9 alternation in Y-maze test. Total number of arm entries and percentage of alternance of 3-month-old
 10 WT and TTL^{+/-} mice. Graph represents mean \pm SEM. $n = 28$ for WT and TTL^{+/-} mice. Student's t test, *** p
 11 < 0.001 , **** $p < 0.0001$. **(E)** Novel Object Recognition test. Recognition index (time spent exploring the
 12 novel object minus the time spent exploring the two familiar objects, in sec) of 3-month-old WT and
 13 TTL^{+/-} mice, measured 1h after familiarization. Mean \pm SEM, $n = 48$ and 40 for WT and TTL^{+/-} mice,
 14 respectively. Student's t test, **** $p < 0.0001$. **(F)** Input/output (I/O) curves of 3-month-old WT and
 15 TTL^{+/-} mice slices. Curves were constructed by plotting mean fEPSPs slopes \pm SEM as a function of
 16 stimulation intensity. Two-way ANOVA, genotype x stimulation intensity interaction is not significant (F
 17 (10, 80) = 0,3845, $p = 0.9500$). $n = 5$ slices from 3 WT mice and $n = 5$ slices from 3 TTL^{+/-} mice. **(G)** Long-
 18 Term Potentiation (LTP) of 3-month-old WT and TTL^{+/-} mice. Curves represent normalized mean of
 19 fEPSPs slopes \pm SEM as a function of time before and after LTP induction. Representative traces from
 20 one experiment are shown. They were extracted at the times indicated (1, 2) on the graph **(H)** Graph
 21 showing normalized mean of fEPSPs slopes \pm SEM for the last 10 min of recording in WT and TTL^{+/-} mice.
 22 Mann-Whitney test, ns = not significant ($p = 0.8048$). $n = 7$ slices from 3 WT mice and $n = 7$ slices from 3
 23 TTL^{+/-} mice. **(I)** Input/output (I/O) curves of 9-month-old WT and TTL +/- mice slices. Two Way ANOVA,
 24 genotype x stimulation intensity interaction (F (10, 220) = 1,923, * $p = 0.0433$). $n = 12$ slices from 5 WT
 25 mice and $n = 12$ slices from 5 TTL^{+/-} mice. **(J)** Long-Term Potentiation (LTP) of 9-month-old WT and TTL^{+/-}
 26 mice. Representative traces from one experiment are shown. They were extracted at the times
 27 indicated (1, 2) on the graph. **(K)** Graph showing normalized mean of fEPSPs slopes \pm SEM for the last 10
 28 minutes of recording in WT and TTL^{+/-} mice. Mann-Whitney test, ** $p = 0.0021$; $n = 10$ slices from 4 WT
 29 mice and $n = 10$ slices from 4 TTL^{+/-} mice.

30

1 **Figure 2. Tubulin tyrosine ligase reduction decreases dendritic spine density *in vivo* and in cultured**
 2 **neurons. (A)** Confocal images showing representative examples of dendritic segments of cortical
 3 neurons from 4-month-old Thy1-eYFP-H WT and Thy1-eYFP-H tubulin tyrosine ligase heterozygous
 4 (TTL^{+/-}) mice. **(B)** Total dendritic spine density, or that of each different morphological type of spines, is
 5 represented for Thy1-eYFP-H WT and Thy1-eYFP-H TTL^{+/-} cortical neurons. Graphs represent mean ±
 6 SEM. *n* = 36 neurons from 4 independent animals of each genotype. Student's t test, * *p* < 0.05; *** *p* <
 7 0.001 and ns = not significant. **(C)** Confocal images showing representative examples of the dendritic
 8 segments of GFP-expressing WT and TTL^{+/-} hippocampal neurons in culture at 17 DIV. **(D)** Total dendritic
 9 spine density, or that of each different morphological types of spines are represented for WT and TTL^{+/-}
 10 hippocampal cultured neurons. Graphs represent mean ± SEM. *n* = 27 and 34 neurons from WT and
 11 TTL^{+/-} embryos from at least 3 independent cultures. Student's t test, * *p* < 0.05; ** *p* < 0.01; **** *p* <
 12 0.0001 and ns = not significant. **(E)** Confocal images showing representative examples of dendritic
 13 segments of DiOilistic labeled WT rat hippocampal neurons in culture at 21 DIV, infected with control
 14 shRNA or shRNA targeting tubulin tyrosine ligase (shTTL1 and shTTL2). **(F)** Total dendritic spine density
 15 or that of each different morphological types of spines, of hippocampal neurons infected with control
 16 shRNA (non-coding shRNA) or 2 independent shRNA lentiviruses targeting tubulin tyrosine ligase (shTTL1
 17 and shTTL2). Graphs represent mean ± SEM. *n* = 71, 124 and 60 neurons from control shRNA, shTTL1
 18 and shTTL2 respectively, from at least 3 independent cultures. Kruskal-Wallis with Dunn's multi-
 19 comparison test, * *p* < 0.05; ** *p* < 0.01; **** *p* < 0.0001 and ns = not significant. Spines assignment to
 20 thin, stubby or mushroom categories was performed according to morphological parameters described
 21 in Figure S5.

22 **Figure 3. Loss of tubulin tyrosine ligase and increased non-tyrosinated tubulin levels in sporadic**
 23 **Alzheimer's disease brain samples. (A)** Representative immunoblot analysis of tyrosinated,
 24 detyrosinated, Δ2 and α tubulin levels in brain homogenates from entorhinal cortex (E), hippocampus
 25 (H), temporal (T) and lateral prefrontal cortex (L) from control, early Alzheimer's disease (Braak I-II),
 26 middle Alzheimer's disease (Braak III-IV) and late Alzheimer's disease (Braak V-VI) patients. In each blot
 27 an internal standard corresponding to a WT sample was used for normalization and considered as 100%
 28 and the values for each unknown sample was calculated as a % of this standard (see material and
 29 methods). **(B-F)** Quantification of tubulin tyrosine ligase (TTL) protein expression, modified tubulins
 30 (tyrosinated, detyrosinated and Δ2 tubulin) and α tubulin levels in each brain region from control and
 31 Alzheimer's disease patients. Graphs represent mean ± SEM. The dependence of protein levels on,
 32 respectively, clinical stage and brain area was quantitated in each case using a linear mixed model, with

1 Braak stage and brain region as fixed effect factors. Boxed p values measure the overall significance of
 2 these factors (type II Wald F test of model coefficients). In each brain area, post-hoc testing of variations
 3 due to individual Braak stages was performed by Dunnett's test of differences with control. Significance
 4 levels are indicated as follows: # $p < 0.05$ and ## $p < 0.01$. $n = 11, 5, 6,$ and 7 for Control, Braak I-II, Braak
 5 III-IV and Braak V-VI Alzheimer's disease patient brains, respectively. Each sample was analyzed in
 6 triplicate. **(G)** Representative images of detyrosinated, $\Delta 2$ tubulin and phospho-tau in pyramidal neurons
 7 of hippocampi from Alzheimer's disease patients. Dual immunostaining of detyrosinated (upper panel)
 8 or $\Delta 2$ tubulin (lower panel) and AT8-reactive phospho-tau, combined with nuclear staining with DAPI,
 9 was performed on sections of control and Alzheimer's disease patient hippocampi. Neurons with low
 10 (white arrowheads), intermediate (white arrows) or high (red arrows) levels of AT8 immunofluorescence
 11 are shown. Scale bar: $50 \mu\text{m}$. **(H)** Relative frequency distribution of phospho-tau (AT8)
 12 immunofluorescence levels (arbitrary units) in pyramidal neurons of control and AD brains. Low,
 13 intermediate, and high phospho-tau groups were defined based on fluorescence intensity. Two-sample
 14 Kolmogorov-Smirnov test, **** $p < 0.0001$. **(I)** Intensity of detyrosinated tubulin (left graph) or $\Delta 2$
 15 tubulin (right graph) immunofluorescence in pyramidal cell bodies of Alzheimer's disease hippocampal
 16 neurons relative to control, shown as a function of AT8 labelling level. Mean \pm SEM. For detyrosinated
 17 tubulin, $n = 382$ and 67 neurons in controls and $n = 296$ and 162 for Alzheimer's disease neurons in low
 18 and intermediate phospho-tau groups, respectively. For $\Delta 2$ tubulin, $n = 249$ and 45 neurons in controls
 19 and $n = 91$ and 133 for Alzheimer's disease neurons in low and intermediate phospho-tau groups,
 20 respectively. Mann-Whitney test, **** $p < 0.0001$.

21 **Figure 4. Loss of tubulin tyrosine ligase and increased non-tyrosinated tubulin levels correlate with**
 22 **inhibition of microtubule dynamics in human cortical APP-London neurons. (A)** Immunoblot analysis of
 23 phospho-specific tau (AT8), total tau (tau46), tubulin tyrosine ligase (TTL), detyrosinated tubulin and $\Delta 2$
 24 tubulin of tubulin tyrosine ligase from lysates of human cortical neurons, derived from WT and APP
 25 London (V717I) knocked-in iPSCs isogenic lines. GAPDH was used for tau and TTL normalization and total
 26 tubulin for modified tubulins. Immunoblot quantifications of phospho-tau normalized to total tau **(B)**,
 27 tubulin tyrosine ligase (TTL) **(C)**, detyrosinated **(D)** and $\Delta 2$ tubulin **(E)**. Data are expressed as a ratio of
 28 WT and graphs represent mean \pm SEM. Data are expressed as a ratio of WT and graphs represent mean
 29 \pm SEM. $n = 5, 5, 4$ and 4 independent neuronal differentiation experiments for B, C, D and E respectively.
 30 Mann Whitney test, ns = not significant, * $p < 0.05$, ** $p < 0.01$. **(F)** WT and APP-London human cortical
 31 neurons expressing EB3-GFP. Representative neurites (dashed boxes) from human cortical neurons were
 32 analyzed for microtubule dynamics and kymographs of these regions are shown below. Scale bar: 10

1 μm . (**G-L**) Parameters of microtubule dynamics are represented as mean \pm SEM. $n = 14$ neurites from WT
 2 and APP-London neurons for **G** to **I**, and $n = 44$ comets for **J**, 42 comets for **K** and 38 comets for **L**, from
 3 WT and APP-London neurons respectively. Student's t-test, ns = not significant, ** $p < 0.01$ and *** $p <$
 4 0.001.

5 **Figure 5. Acute oA β treatment affects spine invasion by dynamic microtubules in neurons. (A)**
 6 Confocal images showing representative examples of dendritic segments of eGFP expressing WT rat
 7 hippocampal neurons (17 DIV) treated with DMSO or with 250 nM of oligomeric amyloid β peptide (1-
 8 42) (oA β) for 2 days. (**B**) Graphs of the percentage of dendritic spine density in WT cultured neurons
 9 incubated with oA β over 6 hours. Data are expressed as a % of baseline and graphs represent mean \pm
 10 SEM. $n = 4$ neurons analyzed over time. One-way ANOVA with Dunnett's multiple comparison test, * $p <$
 11 0.05 and *** $p < 0.001$. (**C**) Representative stills from videos of a WT neuron (21 DIV) transfected with
 12 DsRed and EB3-eGFP to visualize dendritic spines and the growing plus ends of microtubule, before and
 13 2 hours after oA β treatment. Spines that will prune are highlighted with a green arrow at time 0, and
 14 with an empty green arrow after 2 hours of oA β treatment. The spine that will be invaded by a
 15 microtubule is highlighted with a blue arrow at time 0 and persists after 2 hours of oA β treatment.
 16 Microtubule invasion into the spine is highlighted with a red arrow. Spines that are not invaded but
 17 persist after oA β treatment are highlighted with arrows in magenta (**D**) Percentage of spines invaded by
 18 microtubules before and after oA β exposure at the indicated times. Graphs represent mean \pm SEM. $n =$
 19 22, 10, 9, 6 and 5 neurons at each time point. One-way ANOVA with Dunnett's multiple comparison test,
 20 ns = not significant, ** $p < 0.01$ and **** $p < 0.0001$. Number of spines: 402, 150, 411, 191, 321, 342 and
 21 285 for control and A β (0.5h, 1h, 1.5h, 2h, 3h and 6h) conditions, respectively) (**E**) Total percentage of
 22 spine pruning or resistance to vehicle or oA β incubation. Graph represents the mean percentage of non-
 23 invaded spines (left) or microtubule-invaded spine fate (right) for either fate. Spines invaded by
 24 microtubules ($n = 45$ and 24) and spines non-invaded by microtubules ($n = 43$ and 43) for vehicle and
 25 oA β conditions, respectively. Microtubule-invaded spines were significantly more resistant to oA β -
 26 induced pruning than non-invaded spines (overall dependence of the spine pruning rate on microtubule
 27 invasions and oA β treatment: $X^2 = 43.64$, 4 df, **** $p < 0.0001$, chi-square test; odds-ratio of resistance
 28 to oA β in microtubule-invaded vs; non-invaded spines (1.15 vs. 5.44, $X^2 = 5.27$, 1df, * $p = 0.021$, Woolf -
 29 test).

30

1 **Figure 6. Ectopic tubulin tyrosine ligase expression rescues neurons from oA β -induced dendritic spine**
 2 **loss and resumes microtubule invasions into spines. (A-B)** Immunoblot analysis of tubulin tyrosine
 3 ligase (TTL) **(A)** and tyrosinated/detyrosinated tubulin ratio **(B)** from WT mouse cortical neurons (17 DIV)
 4 transduced or not with a lentivirus expressing TTL and chronically treated with DMSO or with 100 nM
 5 oA β . Data are expressed as a % of WT and graphs represent mean \pm SEM. **(A)** $n = 8, 7, 4$ and 4 cultures
 6 for WT, WT+ A β , WT+TTL and WT+A β +TTL respectively. Two Way ANOVA, oA β treatment \times TTL
 7 expression interaction ($F(1, 19) = 14.6$, ** $p = 0.0012$). All values were compared to WT, Dunnett's
 8 multiple comparison test, * $p < 0.05$ and **** $p < 0.0001$. **(B)** $n = 5, 5, 3$ and 3 cultures for WT, WT+ oA β ,
 9 WT+TTL and WT+oA β +TTL respectively. Two Way ANOVA, oA β treatment \times TTL expression interaction (F
 10 $(1, 12) = 1.309$, $p = 0.274$). All values were compared to WT, Dunnett's multiple comparison test, ns =
 11 not significant. **(C)** Graphs of total dendritic spine density in cultured WT neurons treated as in A. Graphs
 12 represent mean \pm SEM. $n = 27, 26, 20$ and 20 neurons for WT, WT+ oA β , WT+TTL and WT+oA β +TTL
 13 respectively. Two Way ANOVA, oA β treatment \times TTL expression interaction ($F(1, 89) = 58.44$, **** $p <$
 14 0.0001). All values were compared to WT, Dunnett's multiple comparison test, ns = not significant and
 15 **** $p < 0.0001$. **(D)** Confocal images showing representative examples of dendritic segments of GFP-
 16 expressing WT hippocampal mouse neurons (17 DIV) chronically treated with DMSO or with 100 nM
 17 oA β . **(E)** Representative stills from videos of rat WT neurons (18 to 21 DIV) transduced or not with a TTL
 18 containing lentivirus and transfected with plasmids encoding eGFP and EB3-tdTomato to visualize the
 19 dendrites and spines and the growing plus ends of microtubule, respectively. Cells were incubated with
 20 vehicle or with 250 nM of oA β for 30 minutes. Microtubule invasions of spines are highlighted with a red
 21 arrow. **(F)** Percentage of spines invaded by microtubules after vehicle or oA β exposure. Graphs
 22 represent mean \pm SEM. $n = 9$ neurons for each condition. Two Way ANOVA, oA β treatment \times TTL
 23 expression interaction ($F(1, 32) = 4.76$, $p = 0.037$). Holm-Sidak's multiple comparison test, ns = not
 24 significant, * $p < 0.05$. **(G)** Graphs of total dendritic spine density in cultured neurons treated as in E and
 25 incubated with vehicle or with oA β for 30 minutes or 3 hours. Graphs represent mean \pm SEM. $n = 6$
 26 neurons of each condition. Two-way ANOVA, oA β treatment \times TTL expression interaction ($F(2, 30) =$
 27 7.11 , $p = 0.003$). Holm-Sidak's multiple comparison test, ns = not significant, **** $p < 0.0001$. For F and
 28 G, number of spines analyzed: $n = 119, 117, 106, 123, 75$ and 106 for control, control + TTL, control + A β
 29 30 min, control +TTL + A β 30 min, control + A β 3 hours and control + TTL + A β 3 hours, respectively.

30 **Figure 7. Schematic representation of tubulin tyrosine ligase, of modified tubulins in dendritic shafts**
 31 **and dendritic spines and of spine density in neurons (normal conditions and under oA β exposure).**
 32 Tyrosinated tubulin dimers polymerize into dynamic tyrosinated microtubules (red). Tubulin

1 carboxypeptidases (VASH-SVP) detyrosinate long lived microtubules (green). After depolymerization,
2 tubulin tyrosine ligase (in grey) retyrosinates tubulin dimers. Very stable detyrosinated microtubules are
3 substrate of cytosolic carboxypeptidases (CCPs) to form $\Delta 2$ microtubules (blue) that exits the
4 tyrosination/ detyrosination cycle.

5 In mature neurons from control patients (or wild type mice), tyrosinated microtubules form a shell at
6 the outer part of the dendrite while detyrosinated and $\Delta 2$ microtubules localize to the inner part. Some
7 dynamic microtubules from the dendrite transiently invade dendritic spines.

8 In neuronal models of Alzheimer's disease, $A\beta$ oligomers exposure have a sequential effect on
9 microtubule behavior and dendritic spine retraction: short time incubation with $A\beta$ oligomers induces a
10 decrease in TTL content, an accumulation of detyrosinated and $\Delta 2$ microtubules, a decrease in the
11 frequency of microtubule invasion into spines with no change in dendritic spine density; longer
12 incubation accentuates this phenotype and induces spine retraction.

13 Ectopically controlled TTL expression restores tyrosinated, detyrosinated and $\Delta 2$ tubulin balance,
14 microtubule invasion into the spines and dendritic spine density.

15

16

Figure 1




Figure 1
182x224 mm (5.4 x DPI)

1
2
3




Figure 2
175x199 mm (5.4 x DPI)

1
2
3
4

Figure 3




Figure 3
182x281 mm (5.4 x DPI)

1
2
3

Figure 4




Figure 4
154x214 mm (5.4 x DPI)

1
2
3

Figure 5 Rat hippocampal cultured neurons




Figure 5
163x179 mm (5.4 x DPI)

1
2
3
4

Figure 6




Figure 6
193x168 mm (5.4 x DPI)

1
2
3
4

Figure 7




Figure 7
200x200 mm (5.4 x DPI)

1
2
3